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The Human Immunodeficiency Virus (HIV) is the main contributor to rising child mortality in 
South Africa.  Although prevention of mother-to-child transmission programmes have been 
implemented in the country, little is known about the clinical and loss to follow-up 
outcomes of infants born to HIV-infected women attending these programmes. 
Purpose 
The purpose of the study was to describe the clinical and loss to follow-up outcomes of 
HIV-exposed infants whose mothers had received antiretroviral therapy or prophylaxis 
during their pregnancy at the Prevention of Mother-to-Child Transmission programme at 
McCord Hospital.  Furthermore, maternal socio-demographic characteristics associated 
with these outcomes were determined.   
Methods 
An observational retrospective cohort study design was used.  The study population 
consisted of infants whose mothers had received antiretroviral prophylaxis or therapy at 
McCord Hospital, and were delivered at McCord Hospital, and/or were brought back to 
McCord Hospital, following delivery from 1 May 2008 to 31 May 2009. 
Results 
Data on 265 infants was analysed.  Of the 220 infants who were tested, the HIV 
transmission risk was 2.7% (n=6; 95% CI: 1.0% to 5.8%) at 6 weeks of age.  Overall, 
40.4% of infants in the cohort were lost to follow-up (n=105, 95% CI: 34.4 to 46.6).  In the 
multivariable model (n=253), late booking for first antenatal visit at or after 28 weeks of 
gestation (adjusted hazard ratio (AHR) 2.3; 95% CI: 1.0 to 5.1, p=0.044) was a risk factor 
for loss to follow-up.  Compared to having an emergency caesarean section, having an 
elective caesarean section (AHR 1.9; 95% CI: 1.1 to 3.5) or normal vaginal delivery (AHR 




The substantial attrition of infants born to HIV-infected mothers in the Prevention of 
Mother-to-Child Transmission programme at McCord Hospital undermined the goals of the 
programme, and underestimated the effect of infectious disease morbidity, mortality and 
HIV transmission risk associated with these infants. 
Recommendations 
Counselling mothers on the health benefits to their HIV-exposed infants of attending the 
follow-up clinic and tracing of infants who have been lost to follow-up is vital to the 
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1 CHAPTER I: INTRODUCTION 
1.1 INTRODUCTION 
Sub-Saharan Africa is severely affected by the Human Immunodeficiency Virus (HIV) 
epidemic.  In South Africa, HIV contributes substantially to child morbidity and mortality.  
Although prevention of mother-to-child transmission (PMTCT) programmes has been 
implemented, there is little information available on the clinical outcomes of HIV-exposed 
infants in terms of morbidity, mortality and HIV transmission.  Moreover, little was known 
about the follow-up outcomes of these infants. 
1.2 BACKGROUND 
1.2.1 Global overview of HIV in women and children 
Unheard of 27 years ago, HIV is responsible for substantial mortality causing an estimated 
25 million deaths worldwide 1, 2.  In 2007, approximately 33 million people (95% 
Confidence Interval (CI): 30 million to 36 million) were living with HIV 1.  Sub-Saharan 
Africa continues to be the most severely affected and is home to 67% of all people living 
with HIV 1.   
Globally, children less than 15 years old accounted for approximately 2.0 million (95% CI: 
1.9 million to 2.3 million) of those living with HIV with an estimated 370 000 (95% CI: 330 
000 to 410 000) children less than 15 years newly infected in 2007 1.  Almost 90% of these 
children infected with HIV live in sub-Saharan Africa 1.   
In September 2000, the Millennium Declaration was adopted by 189 nations during the 
United Nations Millennium Summit 2.  Eradicating HIV/Acquired Immune Deficiency 
Syndrome (AIDS) forms goal six of the Millennium Development Goals (MDGs) 3.  
Globally, there has been some progress towards achieving the MDGs 3.  The incidence of 
new HIV infection was reduced from 2.0 million in 2001 to 1.7 million in 2007 largely due to 
expansion of HIV prevention programmes 3.  Furthermore, annual HIV-related mortality 
decreased from 2.2 million in 2005 to 2.0 million in 2007 3.   
Reductions were also noted in the HIV antenatal sero-prevalence in some African 
countries.  The prevalence of HIV in pregnant antenatal clinic attendees has fallen since 
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2000/2001 in 14 of the 17 countries most affected by the pandemic 3.  In Zimbabwe, the 
antenatal prevalence of HIV dropped from 26% to 18% from 2002 to 2006 respectively 1.  
Similarly, Botswana showed a reduction in HIV prevalence in 15 to 19 year old pregnant 
women from 25% in 2001 to 18% in 2006 1.  Behavioural modifications in Zambia and 
Malawi have also led to reduction in the antenatal prevalence of HIV in these countries 1.  
In children globally, the incidence of HIV infections peaked around 2001, and the recent 
decline was most likely related to fewer HIV infections in women of childbearing ages and 
improved coverage of prevention of mother-to-child transmission programmes 1, 3.  In 
2007, approximately 270 000 children less than 15 years (95% CI: 250 000 to 290 000) 
died from HIV-related causes with 90% of these deaths occurring in sub-Saharan Africa 1.   
1.2.2 HIV in South Africa 
In 2007, there were approximately 5.7 million (95% CI: 4.9 million to 6.6 million) people 
living with HIV/AIDS in South Africa 1.  Although the growth of the epidemic may be 
stabilizing, South Africa has the highest proportion of mother-to-child transmission of any 
country 1.  In 2008, the HIV prevalence among 15 to 49 year old antenatal clinic attendees 
was 29.3% (95% CI: 28.5% to 30.1%) 4.  KwaZulu-Natal remains the worst affected 
province with an antenatal HIV prevalence of 38.7% (95% CI: 37.2 to 40.1) 4.  In contrast 
the Western Cape has an HIV prevalence of 16.1% (95% CI:12.6% to 20.2%) amongst its 
antenatal clinic attendees 4. 
In 2007, there were over 18.2 million children between zero and 18 years living in South 
Africa constituting 39% of the total population. KwaZulu-Natal is home to 22% of the 
children living in South Africa 5.  HIV affects the lives of these children substantially.  In 
2005, there were more than 129 000 children aged between two and four years, and 214 
000 children aged five to nine years living with HIV 6.  In the under-five year age group the 
overall prevalence of HIV was estimated to be 3.4% 7. 
Access to antiretroviral therapy (ART) for those living with HIV has improved considerably 
over the past eight years 8.  The proportion of newly infected children less than 15 years 
receiving antiretroviral therapy increased from 2.1% in 2002/2003 to 37% in 2007/2008 8.  
However, access to antiretroviral therapy varied between provinces, with only 31% of 
newly infected children in KwaZulu-Natal receiving treatment compared to 97% in Western 
Cape 8.  The reason for the high antiretroviral therapy coverage in Western Cape was due 
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to the success of prevention of mother-to-child transmission programmes in the province, 
which has successfully reduced the incidence of HIV in children. In addition, the rollout of 
antiretroviral therapy to children has been well implemented in the Western Cape 8.   
1.2.3 HIV and Prevention of Mother-to-Child Transmission programme in South 
Africa 
The annual under five (child) mortality rate in South Africa increased steadily from 56 per 
1000 live births in 1990 to 67 per 1000 in 2008 9, which highlighted the deteriorating health 
status of the children in South Africa.  HIV was the main contributor to the rise in child 
mortality and was estimated to be responsible for 40% of the under-five mortality in 2000 
10.   
In 2000, South Africa adopted the MDGs including reducing child mortality by two-thirds 
(MDG four), and combating HIV and AIDS by 2015 3.  South Africa was one of 12 
countries with an increase in the child mortality rate since the 1990 baseline for the MDGs 
11 and it is unlikely, as a result, that MDG four will be achieved by 2015.  The reasons for 
this failure are complex but HIV/AIDS and poor implementation of prevention of mother-to-
child transmission interventions have contributed to increasing child mortality 11.   
The South African National Prevention of Mother-to-Child Transmission programme aimed 
to alleviate some of the burden of HIV in South Africa 10, 12.  Prior to April 2008, the South 
African national policy for Prevention of Mother-to-Child Transmission advocated the use 
of a single dose of nevirapine to mothers at the onset of labour, and a single dose of 
nevirapine to the newborn baby within 72 hours of delivery 12.  The HIVNET 012 
randomised trial reported the efficacy of the sd-nevirapine regimen.  It reduced the risk of 
perinatal HIV transmission among breastfeeding women in Uganda by 47% at four months 
and by 41% at 18 months (n=645) 13. 
In South Africa, poor leadership, the lack of a comprehensive policy framework, and 
ineffective implementation of the National Prevention of Mother-to-Child Transmission 
programme led to poor coverage and gaps in the programme 11.  These gaps included 
problems with uptake of HIV testing pregnant woman, inappropriate or no use of sd-
nevirapine and limited follow-up care of mothers and their infants 11.  For instance, 
statistics showed that 94% of pregnant women in South Africa had at least one antenatal 
clinic visit in 1998 14.  Of the 52 districts in South Africa, only seven tested more than 80% 
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of antenatal women for HIV and only 68% of pregnant women receiving antenatal care had 
an HIV test performed in 2005/2006 15.  Sixty-one percent of HIV-infected women took sd-
nevirapine during labour, but the proportion dropping out of care was large, with only 47% 
babies born to HIV-infected women receiving nevirapine after delivery 16.   
In April 2008, a new protocol on prevention of mother-to-child transmission was adopted 
nationally, which better reflected World Health Organisation recommendations 12, 17.  The 
main change to the national protocol was the addition of a short course of zidovudine 
(AZT) to be given antenatally and to replace the single intrapartum dose of nevirapine for 
all pregnant women with CD4+ counts above 200 cells/mm3, from a gestational age of 28 
weeks or more.  These new South African guidelines did not include a World Health 
Organisation recommendation that mothers should receive an antiretroviral “tail” 
comprising zidovudine and lamivudine for seven days post partum 17. The zidovudine dose 
administered to the infant depended on the duration of the zidovudine given to the mother 
during the antenatal period.  If the mother received less than four weeks zidovudine 
antenatally, the infant was to be given four weeks of zidovudine postpartum.  Alternatively, 
an infant born to a mother who received more than four weeks of zidovudine was given 
zidovudine for one week postpartum 12. According to one modelling exercise, the lives of 
37 200 children could be saved by 2015 by scaling up prevention of mother-to-child 
transmission that included dual therapy and improving infant feeding strategies1 in South 
Africa 11. 
In April 2010, the National Prevention of Mother-to-Child Transmission guidelines were 
again revised to be far more comprehensive 18.  These guidelines now include the 
provision of triple antiretroviral therapy for women with CD4+ count less than or equal to 
350 cells/mm3 for life; or zidovudine from 14 weeks of pregnancy with sd-nevirapine and a 
tail for women with CD4+ count greater than 350 cells/mm3 18.  The guideline on infant 
antiretroviral prophylaxis has also been revised to include nevirapine to the infant for 6 
weeks in the non-breastfed infant or if the mother is receiving lifelong antiretroviral therapy 
18.  In breastfed infants, oral nevirapine should be provided as long as the mother is 
breastfeeding for up to one year 18.   
                                                 
1
 Prevention of mother-to-child transmission of HIV by dual therapy at 95% coverage, exclusive 
breastfeeding at 50%, exclusive replacement feeding at 40%, and mixed feeding at 10% 
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1.2.4 Prevention of Mother-to-Child Transmission services at McCord Hospital 
McCord is a state-aided hospital with substantial autonomy mostly due to funding received 
from the private sector as well as from many donor agencies.  This autonomy put McCord 
Hospital in a unique position to diverge from national Prevention of Mother-to-Child 
Transmission policy where appropriate and respond more rapidly to reported evidence-
based improvements in changing therapeutic regimens.  The Prevention of Mother-to-
Child Transmission guidelines implemented at McCord Hospital, before the state adopted 
the World Health Organisation recommendation of dual therapy, were based on evidence 
from international studies 19, 20.  Pregnant women with a CD4+ count greater than 200 
cells/mm3 were initiated on a prophylactic antiretroviral regimen.  The regimen chosen 
depended on the mother’s viral load and the gestational age at which she presented for 
antiretroviral treatment.219, 20  Moreover, HIV-infected pregnant women were offered a 
choice of normal vaginal delivery or elective caesarean section (before labour and before 
rupture of membranes) based on their viral load at 36 weeks, and affordability of the 
surgical procedure to the mother.  Newborn infants whose mothers received less than four 
weeks zidovudine antenatally were administered four weeks zidovudine postpartum.  An 
infant whose mother received more than four weeks zidovudine antenatally was given 
zidovudine for one week post partum.  These pregnant women also received intensive 
counselling regarding infant feeding.
3
  
During 2004 to 2005 at McCord Hospital over 90% of mothers at McCord Hospital reported 
that they intended to exclusively formula feed their infants, a finding that reflected the 
message given to these women during counselling about the risks of HIV transmission 
                                                 
2
 Option A. CD4 count ≤ 200: HAART for life:  stavudine, lamivudine & nevirapine.   
Option B. CD4 count >200: decision depends on the viral load (VL):  
• VL <1500 copies/ml: zidovudine monotherapy from 28 weeks until birth and SD-
nevirapine at birth and lamivudine and zidovudine tail for 7 days.  
• VL ≥1500 copies/ml: Combivir (zidovudine/lamivudine) & efavirenz (EFV) from 28 
weeks until birth and zidovudine/ lamivudine tail for 7 days.  
Option C. Women who present late (after 38 weeks gestation / in labour): sd- nevirapine in 
labour with a lamivudine and zidovudine tail of 7 days. 
 
3
 Giddy J, 2009.  Personal communication, June 10 2009 
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through breastfeeding 21.  The effects of this policy and practice on infant morbidity and 
mortality has not been assessed.   
The 2004/2005 cohort of pregnant mothers who received antiretroviral prophylaxis studied 
at McCord Hospital showed that the implementation of modified therapeutic regimens had 
reduced the transmission of HIV from mother-to-child to 2.9% (95% CI: 1.3 to 6.2) at six 
weeks 21.  The low level of HIV vertical transmission was in line with that reported in 
resource rich settings despite the fact that McCord Hospital serves a mixed but lower 
middle class population in a predominantly developing country 22-24.  
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1.3 STATEMENT OF THE PROBLEM 
The reduction of mother-to-child transmission of HIV is one of the key priority areas of the 
National Strategic Plan for HIV in South Africa 25.  According to the plan, scaling up 
coverage and improving Prevention of Mother-to-Child Transmission programmes is one 
of the goals to reduce mother-to-child transmission to less than 5% 25.  Furthermore, a key 
objective of the plan is the expansion of Prevention of Mother-to-Child Transmission 
guidelines to provide care to mothers and infants beyond six weeks 25.  In line with the 
goals of National Strategic Plan, there was an opportunity at McCord Hospital to study the 
follow-up care of infants born to mothers who attended the Prevention of Mother-to-Child 
Transmission programme at McCord Hospital. 
In May 2008, McCord Hospital established a new clinic to offer follow-up health care to 
HIV-infected mothers and their infants.  Women who enrolled antenatally in the Prevention 
of Mother-to-Child Transmission programme and their infants were invited to attend the 
Well Mother and Baby Clinic (Mamanengane) following delivery to receive care for 
themselves and their infants until the children reached 18 months of age. The clinic offered 
ongoing postnatal HIV-care for mothers and their infants.  Services offered included 
antiretroviral treatment for the mother, primary health care, reproductive health services, 
psychosocial support, and health promotion services.  Socio-demographic, behavioural, 
clinical and immunologic data on mothers and their infants were collected as part of the 
standard level of care.   
Whilst the implementation of the Prevention of Mother-to-Child Transmission programme 
at McCord Hospital from 2005 to 2007 reduced the transmission of HIV from mother to 
child to between 1.3% to 6.2% at six weeks of age, data on the clinical outcomes and 
proportion of loss to follow-up of the infants beyond six weeks were not recorded.  
Furthermore, 39% of the mothers in the Prevention of Mother-to-Child Transmission 
programme who delivered at McCord Hospital did not return with their infants for follow-up 
care at six weeks of age
4
.  Given this substantial proportion of mothers and infants lost to 
follow-up, the six-week HIV transmission risk at McCord Hospital may have been 
underestimated.  The new postnatal service provided an opportunity to study the clinical 
outcomes of the infants born to mothers in the Prevention of Mother-to-Child Transmission 
                                                 
4
 Thrumbra M, McCord Hospital, 2009.  Personal communication, 22 June 2009 
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programme and the socio-demographic characteristics associated with loss to follow-up of 
infants attending the clinic.   
1.3.1 Research Questions 
i. What are the clinical outcomes of infants born to HIV-infected women who follow-
up at McCord Hospital for a minimum of six months? 
ii. What are the maternal demographic, socioeconomic, clinical and immunologic 
characteristics associated with loss to follow-up of infants at McCord Hospital? 
1.4 PURPOSE OF THE RESEARCH 
The purpose of the study was to measure the clinical and loss to follow-up outcomes of 
infants, born to HIV-infected mothers who received antiretroviral prophylaxis and therapy 
in the McCord Hospital Prevention of Mother-to-Child Transmission programme, from 1 
May 2008 to 31 May 20095.  Furthermore, the maternal demographic, socio-economic, 
clinical and immunological characteristics associated with these outcomes were examined.   
1.5 SPECIFIC OBJECTIVES OF THE RESEARCH 
The specific objectives were: 
(1) To determine the morbidity, mortality and HIV transmission risk of infants presenting to 
McCord Hospital; 
(2) To determine the loss to follow-up outcomes of these infants presenting to McCord 
Hospital; and 
(3) To measure the association between infants who were lost to follow-up and maternal 
demographic, socio-economic, clinical and immunologic characteristics. 
 
                                                 
5
 All infants included in the study were born from 1 May 2008 to 31 May 2009, either at McCord 
Hospital or elsewhere.  All HIV-infected women whose infants were included in the study received 
antiretroviral therapy or prophylaxis at McCord Hospital. 
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1.6 ASSUMPTION UNDERLYING THE STUDY 
• The demographic, socio-economic (including employment status) and residence of 
the mothers remained unchanged for the duration of the study. 
• Antiretroviral prophylaxis for prevention of mother-to-child transmission or 
antiretroviral therapy was received and taken by the women in the study and was 
adhered to for the duration of her pregnancy. 
• The caregiver correctly reported maternal feeding practice. 
• Infant caregivers remained the same throughout the duration of the study for 
infants not lost to follow-up. 
1.7 OPERATIONAL DEFINITIONS USED IN THE STUDY 
Maternal antiretroviral regimen: 
The antiretroviral regimen prescribed to pregnant women according to clinical guidelines 
followed by McCord Hospital. The regimen was as follows: 
Option A. CD4+ count ≤ 200: antiretroviral therapy:  stavudine, lamivudine and nevirapine  
Option B. CD4+ count >200: decision depended on the viral load (VL): 
VL <1500 copies/ml: zidovudine from 28 weeks until birth and sd-nevirapine at birth, and 
lamivudine and zidovudine tail for seven days.  
VL ≥1500 copies/ml: Combivir (zidovudine/ lamivudine) and efavirenz (EFV) from 28 
weeks until birth, with zidovudine/ lamivudine tail for seven days.  
Option C. Women who present late (after 38 weeks gestation / in labour): sd- nevirapine in 
labour with a tail of zidovudine/ lamivudine for seven days.   
The booking gestational age was the gestational age of the foetus at the woman’s first 
presentation for antenatal care at any health care facility determined by estimation of the 
date of the women’s last known menstrual period or ultrasound estimation. 
Baseline CD4 + count were the CD4+ count measure taken at the mother’s first antenatal 
visit (McCord Hospital or other antenatal clinic). 
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Baseline viral load was the viral load measure taken at the mother’s first antenatal visit to 
clinic (McCord Hospital or other antenatal clinic). 
Any illnesses during pregnancy was any maternal illness requiring treatment during or 
prior to pregnancy excluding World Health Organisation stage IV conditions. 
The maternal baseline height was the height measured in metres at the woman’s first 
presentation to any facility offering antenatal services. 
The baseline maternal weight was the weight measured in kilograms at the woman’s first 
presentation to any facility offering antenatal services. 
Infant heel stick samples were tested for HIV-1 DNA by using polymerase chain reaction 
(PCR) 26. 
The timing of HIV testing of infants was at six weeks and 14 weeks of age.  
Infants were presumed HIV infected if they tested HIV-infected at six or 14 weeks of age 
followed by a confirmatory DNA PCR assay. 
An infant was classified as HIV-infected if one or more antibody tests were positive at or 
after 18 months. 
An infant was presumed HIV-1 uninfected if they had two or more negative DNA 
polymerase chain reaction assays at McCord Hospital with one test performed at six 
weeks of age and the second test performed at 14 weeks of age.  For breastfed infants, 
the DNA PCR assays were taken six weeks after cessation of breastfeeding. 
A child was classified as HIV-1 uninfected if one or more antibody tests were negative 
at or after 18 months. 
Definitive diagnosis of infection: In order for a diagnosis to be classified as definitive, 
the organism needed to be identified, or serologic, and/or antigenic evidence needed to be 
found in the majority of the cases.  The diagnosis was also classified as definitive if the 
clinical picture was pathognomonic of the causative agent (for instance Koplik’s spots on 
buccal mucosa in measles) 27. 
11 
 
Presumptive diagnosis of infection: If the above criteria were not met, the diagnosis of 
infection was classified as presumptive 27. 
The infant morbidity for the purposes of the proposed study was defined as the following 
conditions and was based on a cohort study in Latin America 27. 
Gastrointestinal Acute or chronic gastroenteritis, presumed: cause not identified. 





Otitis media, acute, clinical: diagnosed through physical 
examination.  Specific organism not identified. 
Otitis media with effusion: diagnosed through physical examination 
Tonsillitis/ pharyngitis, presumed, unknown cause 






Bronchiolitis, presumed. Specific cause unknown 
Bronchitis, presumed: cause not determined 
Asthma, presumed 
Pneumocystis jiroveci pneumonia: clinical diagnosis 
 
Skin and mucous 
membranes 
Conjunctivitis, presumed. Clinical diagnosis 
Dermatitis, other 












Other Conditions not included in the above categories 
 
The researcher assigned the loss to follow-up status of infants based on the date of the 
infant’s next scheduled visit.  Infants who missed a scheduled visit but subsequently 
presented for a visit (either scheduled or unscheduled) to McCord Hospital were not lost to 
follow-up.  The initial follow-up periods were at one, six, ten and 14 weeks.  If the infant did 
not return within two weeks of these scheduled visits, the infant was lost to follow-up in the 
study.  Infants who were brought back to McCord Hospital outside of their appointment, 
but within the two-week period of their scheduled appointment were not considered lost to 
follow-up.  Infants brought back to McCord Hospital outside this two-week period were 
classified as lost to follow-up, irrespective of the reason for the delayed visit. 
The later infant follow-up periods were at six, nine, 12, 15 and 18 months.  If the infant 
did not return within one month of these scheduled visits, the infant was lost to follow-up in 
the study.  Infants who were referred to other clinics by clinicians or were discharged from 
the clinic at 18 months were not considered lost to follow-up.   
Vaccination coverage:  the numerator was the number of children that reached the 
specified time point who had received the specified vaccine(s), according to data from a 
Road-to-Health card or report by the mother. The denominator was the total number of 
children who reached the specified time point 28. 
1.8 ORGANISATION OF THE REPORT 
This dissertation is divided into six chapters.  Chapter one provides an overview of HIV in 
the context of child health globally and locally.  This chapter also outlines the research 
questions, main objectives and purpose of this study.  
Chapter two outlines the body of knowledge related to consequences of HIV on infant and 
child health.  Furthermore, literature on loss to follow of infants in operational prevention of 
mother-to-child transmission settings and characteristics of patients lost to follow-up is 
critically analysed.   
Chapter three describes the methods undertaken in this research study.  The study 
design, study population, data sources, sampling methods, variables and statistical 
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analysis applied by this study are further explored in this chapter.  The reliability and 
validity of the study and handling of bias and limitations are also described.   
Chapter four focuses on the results of the research study.  The overall study population is 
described and infant outcomes in terms of morbidity, mortality, HIV transmission, and loss 
to follow-up are outlined.  Furthermore, risk factors associated with loss to follow-up of 
infants and predictors of upper respiratory tract infection are determined.   
Chapter five outlines the finding of the study and discusses these results in relation to 
previous studies and importance of these results for South Africa. 
Chapter six provides recommendations and conclusions based on the results of the study. 
1.9 SUMMARY 
HIV remains a leading cause of child mortality in South Africa.  This chapter outlined both 
the global and local burden of disease and the extent and limitations of Prevention of 
Mother-to-Child Transmission programme in South Africa. 
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2 CHAPTER II: LITERATURE REVIEW 
2.1 INTRODUCTION 
The Prevention of Mother-to-Child Transmission programme at McCord Hospital has had 
success in reducing the mother-to-child transmission risk of HIV to less than 5%.  This 
meant that the number of HIV-exposed, uninfected children born to HIV-infected women 
who attended the Prevention of Mother-to-Child Transmission programme at McCord 
Hospital exceeded the number of HIV-exposed but infected children born to these women.  
In a developing setting, HIV-exposed uninfected infants are vulnerable to acquiring 
infectious diseases.  The clinical outcomes of this cohort of HIV-exposed, uninfected 
children at McCord Hospital were not previously studied.  This study was therefore 
important in contributing to the body of knowledge regarding the clinical outcomes of HIV-
exposed, uninfected children.   
Children born to HIV-infected women were seldom identified as a potentially high-risk, 
vulnerable group who need ongoing health care after their mothers leave the Prevention of 
Mother-to-Child Transmission service.  Losing these infants to follow-up care represented 
a missed opportunity for ongoing care and undermined the goals of the programme to 
reduce HIV-related incidence, morbidity and mortality.  Thus, identifying the socio-
demographic, clinical and immunological characteristics of the mother that were 
associated with high levels of attrition was necessary.  The knowledge obtained enables 
health care workers to identify high-risk patients and implement measures to reduce loss 
to follow-up.   
2.2 PURPOSE OF THE LITERATURE REVIEW 
The purpose of the literature review was to examine the literature on infant feeding, 
morbidity and mortality particularly in HIV-exposed, uninfected infants, and loss to follow-
up of infants in a prevention of mother-to-child transmission programme.   
Studies examining the health outcomes of HIV-exposed, uninfected infants were critically 
reviewed to determine the risk factors associated with morbidity and mortality of these 
infants.  Studies exploring the loss to follow-up children born to mothers in prevention of 
mother-to-child transmission programmes were also critically reviewed to determine the 
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risk factors associated with loss to follow-up from the facility where the child had been 
born. 
2.3 SCOPE OF LITERATURE REVIEW 
Literature assessing morbidity and mortality in HIV-infected and uninfected infants and 
loss to follow-up of infants in Prevention of Mother-to-Child Transmission programmes 
were reviewed.  Moreover, predictors of morbidity and mortality and loss to follow-up of 
these infants were explored. 
2.4 SOURCES OF LITERATURE REVIEWED 
The Pubmed database was searched for studies between 1990 and 2010 pertaining to 
factors associated with loss to follow-up of infants in Prevention of Mother-to-Child 
Transmission programmes, and the morbidity of HIV-exposed, uninfected infants in terms 
of infectious and non-infectious disease.  The following search terms were used to find 
citations related to morbidity of HIV-exposed infants: “respiratory tract infections”, 
“diarrhoea”, “infectious disease” “non-communicable disease”, “infant morbidity” and “HIV-
uninfected infants”.  The Pubmed database was also searched for citations related to loss 
to follow-up: “Prevention of Mother-to-Child Transmission”, “follow-up”, “drop-out”, and 
“loss to follow-up”. 
2.5 LITERATURE REVIEWED 
2.5.1 Modes of transmission of HIV from mother-to-child 
Transmission of HIV can occur in utero (5%), during the intrapartum period (15%) and in 
the postpartum period during breastfeeding (15%) 29.  The combined risk of mother-to-child 
transmission of HIV without any interventions in non-breastfed populations is 15 to 30% 17.  
The combined risk of transmission in the absence of interventions, in breastfed 
populations who practice prolonged breastfeeding is 35% 29.   
Transmission of HIV can be reduced in utero and intrapartum from 20% to between 7 and 
9% by implementing short course prophylactic antiretroviral therapeutic regimens 
administered to the mother during pregnancy and the infant immediately postpartum 30.  A 
combination of interventions, including antiretroviral therapy that optimally suppressed viral 
load, elective caesarean section and complete avoidance of breastfeeding can reduce 
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vertical transmission of HIV to infants to 1 to 2% in developed countries 22, 24, 31-34.  
However, infants in the postpartum period are still particularly vulnerable to HIV due to risk 
imparted by prolonged breastfeeding.  In parts of Africa, where prolonged breastfeeding 
for 18 to 24 months is still the norm, HIV transmission through breast milk imposes a 
further risk of approximately 10-15% 35-37. 
In 2006, an estimated 39% of pregnant women attending antenatal clinics in KwaZulu-
Natal were HIV-infected compared to the national average of 29% 38.  A prospective cohort 
study of mother–infant pairs who participated in the South African national Prevention of 
Mother-to-Child Transmission programme for the period 2002 to 2004 described the 
mother-to-child transmission of HIV as 11.8% (68 out of 585) at three to four weeks.  The 
rate of early transmission of HIV to infants at three to four weeks of age ranged from 8.6% 
(95% CI: 4.5% to 14.5%) in Paarl, 11.9% (95% CI: 8.3% to 16.3%) in Umlazi to 13.7% 
(95% CI: 8.9% to 19.8%) in Rietvlei 39. 
2.5.2 Predictors of mortality in infants born to HIV-infected mothers 
Findings of several studies have highlighted the factors affecting mortality of HIV-exposed 
infected and uninfected infants 40-43.   
Findings of the studies showed maternal death, advanced maternal HIV disease, and 
anaemia were significantly associated with infant mortality. A meta-analysis of 3468 infants 
in seven randomised intervention trials of mother-to-child transmission in sub-Saharan 
Africa showed that 35% of HIV-infected infants and 4.9% of HIV-uninfected infants were 
estimated to die by one year of age 41.  Infant mortality was associated with maternal death 
(adjusted odds ratio (AOR) 2.3; 95% CI: 1.6 to 3.2; p < 0.001), and maternal CD4+ cell 
count less than 200 cells/mm3 (AOR 1.91; 95% CI: 1.4 to 2.6; p < 0.001) 41.  Moreover, 
infant mortality was greater in infants whose mothers had advanced disease or died during 
follow-up, regardless of their HIV status.  The effect of maternal death on infant mortality 
was considerable in the group of uninfected infants (AOR 3.6; 95% CI: 1.9 to 6.9; p < 
0.001) 41.   
Timing of HIV transmission risk may also affect infant mortality.  Late (breastfeeding) 
transmission of HIV was significantly associated with lower infant mortality when compared 
to early (perinatal) transmission (AOR 0.52; 95% CI: 0.29 to 0.70; p<0.0001) 41.  The 
children included in this meta-analysis were part of research studies where health care 
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support was likely to be better than existed in the routine health care setting.  The 
estimates of infant mortality were therefore lower than estimates of mortality in real-life 
settings.   
The findings of a cohort study conducted in Lusaka, Zambia were in agreement with the 
meta-analysis described above.  The cohort of 620 HIV-uninfected infants were recruited 
as part of a randomised controlled trial investigating early cessation of breastfeeding 40.  
The study findings showed that infants born to mothers with CD4+ cell count less than 350 
cells/mm3 were at greater risk for death (hazards ratio 2.9; 95% CI: 1.0 to 8.0) 40.  
Cumulative mortality was 4.6% (26/620) (95% CI: 2.8% to 6.3%) by four months of age 40.  
Causes of death was known in 20 infants, the most frequent of which was pneumonia 
(10/20) and sepsis (4/20) 40.  In multivariate analysis, maternal haemoglobin <10 g/dL 
(hazards ratio 2.37; 95% CI: 1.0 to 5.4), maternal death (hazards ratio 6.8; 95% CI: 2.7 to 
17.7) and birth weight < 2500 g (hazards ratio 2.4; 95% CI: 1.1 to 5.7), was also 
significantly associated with mortality of the infant through four months of age 40.  A 
limitation of this study was that the cohort of uninfected infants born to uninfected mothers 
was followed until four months of age only, hence morbidity and mortality of these infants 
beyond this age remains unknown.  Moreover, although infants had frequent heel-stick 
blood samples tested for HIV-1 DNA at birth, one week, and one, two, three and four 
months of age by polymerase chain reaction, unidentified HIV infection that contributed to 
morbidity and mortality in the cohort could not be ruled out 40.   
Maternal HIV-infection may increase infant mortality regardless of the infants HIV status.  
The findings of a prospective cohort study in a rural Uganda showed that the two-year 
child mortality rate was 540 per 1000 HIV-infected children (n=69), 165 per 1000 children 
in HIV-uninfected infants born to HIV-infected mothers (n = 269) and 128 per 1000 children 
born to HIV negative mothers (n=3183) 43.  Relative to uninfected mothers, the hazard ratio 
of child mortality was 2.0 (p < 0.001) in HIV-exposed but uninfected infants, and 3.8 (p < 
0.001) if the infant was infected 43.  A limitation of this  study was the loss to follow-up of 
HIV-infected infants resulting in a small sample size in this group 43.  Similar findings were 
observed in a retrospective cohort analysis of 13 583 children under two years of age in 
rural, northern KwaZulu-Natal 44.  The data from this study showed that mortality of 
children under 2 years (n=848; 6.2%) was independently associated with maternal HIV 
status (adjusted hazards ratio (AHR) 4.3; 95% CI: 3.1 to 6.0) 44. 
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Infant receipt of cotrimoxazole prophylaxis may be a predictor of infant mortality.  
According to the findings of a randomised controlled trial comparing cotrimoxazole 
prophylaxis (n=265) to a placebo (n=269) in HIV-infected children in Zambia, 
cotrimoxazole prophylaxis was associated with lower mortality (cause-specific hazard ratio 
0.6; 95% CI: 0.4 to 0.8; p < 0.001) 45. Data from a clinic-based, multi-centre prospective 
cohort conducted in Puerto Rico, Texas, Illinois, Massachusetts and New York over an 11 
year period showed that infant receipt of cotrimoxazole prophylaxis for Pneumocystis 
jiroveci pneumonia was associated with reduced risk of death (relative risk 0.04; 95% CI: 
0.0 to 0.3; p = 0.002) 42.   
2.5.3 Infant morbidity of HIV-exposed but uninfected infants 
Infants born to HIV-infected women may be at greater risk for morbidity due to various 
factors.  These HIV-exposed infants are vulnerable to losing one or both parents to HIV-
related mortality 46.  In addition, HIV-infected mothers may not be able to provide 
appropriate childcare or may transfer infectious pathogens to their infants 41.   
A two-year prospective cohort study in Latin America and the Caribbean countries 
described the clinical outcomes of HIV-exposed but uninfected infants born to HIV-infected 
women.  The study outcome measure was infectious disease, either definitely or 
presumptively diagnosed, occurring at birth, six to 12 weeks, and six months of age 27. 
The study population consisted of 462 HIV-exposed but uninfected infants 27.  None of the 
infants was breastfed.  All except one of the infants were administered zidovudine 
prophylaxis.  The remaining infant received nevirapine prophylaxis.  The infections were 
classified according to age of diagnosis as early neonatal (zero to six days), late neonatal 
(seven to 27 days), and post-neonatal (greater than 28 days) 27.  Sixty one percent (283 of 
462) of infants developed 522 infections (1.8 infections per infant).  The cumulative 
incidence rate of infections was 4.5 infections per 100 child-weeks of observation 27. 
Skin or mucous membrane infections were most common (1.9 cases per 100 child-weeks) 
followed by respiratory tract infections (1.7 cases per 100 child-weeks) 27.  Early neonatal 
sepsis occurred in 12 infants (26 cases per 1000 infants) 27.  Overall, hospitalisations 
occurred in 17% (81 of 462) of the infants with more admissions occurring in infants with 
lower respiratory tract infections (41%).  Advanced maternal HIV disease (AOR 2.1; 95% 
CI: 0.9 to 4.5), infant anaemia (AOR 2.3; 95% CI: 1.4 to 3.8), tobacco smoking antenatally 
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(AOR 2.2; 95% CI: 1.3 to 3.8), and overcrowding (AOR 1.5; 95% CI: 0.9 to 2.4) were 
independently associated with more than one neonatal infection 27.  Post-neonatal 
infections were associated with the use of intrapartum antibiotics (AOR 1.7; 95% CI: 1.2 to 
2.5) and lower maternal CD4+ counts (AOR 1.7; 95% CI: 0.8 to 3.6) 27. 
A limitations to the study was selection bias 27.  The mothers volunteered to enrol in the 
study and there was no control group of HIV-1 uninfected mothers.  The strength of the 
research was its prospective study design and analysis where data were collected 
prospectively starting antenatally 27.  Presumptive and confirmed diagnoses of infections 
were included in the study to avoid underestimation of the occurrence of disease 27.  Early 
onset respiratory conditions without systemic signs or radiographic findings were not 
included to avoid differential misclassification bias 27. 
An analysis of a cohort of infants (n=620) in a randomised trial of breastfeeding cessation 
in Lusaka, Zambia showed that HIV-uninfected infants had a greater risk of hospital 
admissions (hazards ratio 2.3; 95% CI: 1.2 to 4.4) if maternal CD4+ count was less than 
350 cells/mm3, after adjusting for maternal death and low birth weight 40.  Cessation of 
breastfeeding before four months of age was also significantly associated with time to first 
hospital admission (hazard ratio 3.4; 95% CI: 1.0 to 11.5) in the adjusted analysis 40.  
Thirty-nine infants were admitted to hospital between four days and four months of age 40.  
The most common cause of admission was pneumonia and sepsis (31 of 39) 40.   
A prospective cohort study of 808 children in a clinical setting in Blantyre, Malawi 
assessed the patterns of morbidity in HIV-infected and uninfected infants over 18-months 
of age 47.  HIV infected children (n=190) had more frequent events of age-adjusted 
recurrent fever, chronic diarrhoea, vomiting, ear infections, skin conditions, oral thrush and 
cough relative to HIV-uninfected children (n=499) (p < 0.05) 47.  However, there was no 
significant difference between illness events in HIV-exposed but uninfected children and 
children born to HIV-seronegative mothers (n=119) 47.  The strength of this study was the 
large number of infants followed up to 18 months of age 47.  However, a large proportion of 
children (n=184) (23%) were lost to follow-up over the 18 month period 47.  In addition, the 
number of maternal deaths in the HIV-uninfected infant group was small (n=23) and hence 
may not have shown an effect on the survival of these infants 47.   
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2.5.4 Loss to follow-up of mothers and infants in Prevention of Mother-to-Child 
Transmission interventions 
HIV-infected children were rarely identified for ongoing health care after leaving the care of 
a prevention of mother-to-child transmission service.  A 13-month retrospective record 
review (N = 1234) of HIV-infected women who attended the Prevention of Mother-to-Child 
Transmission programme was conducted at Coronation Women and Children’s Hospital in 
Johannesburg in 2002 48.  Of the 8221 deliveries at this hospital in the 13-month period, 
1234 (15%) occurred in HIV-infected women 48.  The mother-to-child transmission risk of 
HIV was 8.7% at six weeks and 8.9% at three months of age 48.   By four months of age, 
more than 70% of infants were lost to follow-up in the routine Prevention of Mother-to-
Child Transmission service 48.   
From 2002 to 2003, a prospective cohort study was conducted of infants born to mothers 
in the Prevention of Mother-to-Child Transmission service at Coronation Women and 
Children’s Hospital 49.  Three-hundred infants born to HIV-infected women in the 
Prevention of Mother-to-Child Transmission service at the hospital were followed up to 12 
months of age 49.  Of the 300 infants, 233 (78%) remained in with study at 12 months of 
age 49.  At the 12-month visit, mothers who returned with their infants were asked 
questions about their socio-economic circumstances 49.  Cross-sectional data were 
collected from 176 (76%) of the 233 patients with a semi-structured interview 49.  Of the 
176 mothers interviewed, 101 were unemployed (57%), 103 (58.5%) were living with the 
father of the infant at the time of the interview and 117 (67%) of women had disclosed their 
HIV-infection status to their partners 49.  The primary caregiver was the mother in 150 of 
the 176 infants (85.2%).  Most of the mothers who returned to Coronation Women and 
Children’s Hospital at the 12-month visit resided in Johannesburg (n=102, 58%), with 32 
mothers (18.2%) residing in another province 49.  The major limitation to this study was that 
it evaluated the socio-demographic profile of women who returned to the hospital at 12 
months and were therefore not representative of women who were lost to follow-up 49.  
The authors of this study concluded that the results of the study were not generalisable to 
other situations.   However, the findings of this study highlighted the socio-economic 
circumstances of HIV-infected women and their infants.49 
A prospective cohort study conducted  in 1994 examined the predictors of loss to follow-up 
of HIV-exposed infants in Malawi 50.  HIV infection status could not be determined for 797 
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infants (37%) of 2156 infants in the study as 653 of these 797 infants (30%) were not 
brought back for follow-up care 50.  Social and biological variables as predictors of loss to 
follow-up were assessed.  Infants with lower birth weight (odds ratio (OR) 0.8; p=0.003) 
and singletons (OR 0.7; p=0.09) were less likely to receive follow-up care.  Furthermore, 
the parents of infants lost to follow-up were less educated (OR 1.2; p<0.001) and were 
more likely to be farmers (OR 4.0; p < 0.001) 50.   
A retrospective cohort study conducted from 2000 to 2005 examined the loss to follow-up 
proportion of mother-infant pairs (N=567) in the Prevention of Mother-to-Child 
Transmission programme in rural Uganda 51.  Maternal antenatal data, HIV diagnosis, 
antiretroviral history, delivery and follow-up of mother-infant pairs were retrospectively 
collected from medical records 51.  The study definition for loss to follow-up was “those with 
unknown infant HIV status at 18 months of age and who had missed their last scheduled 
appointment for greater than or equal to two months before the start of the study 51.”  
Mother-infant pairs who were lost to follow-up were actively traced, and a cross-sectional 
survey was then conducted to determine the reasons for loss to follow-up in the Prevention 
of Mother-to-Child Transmission programme 51.   
Overall, loss to follow-up of mother-infant pairs was 54% (n=303) after a median duration 
of one month (interquartile range (IQR) 0-5) 51.  There were 197 mother-infant pairs 
successfully traced.  Timing for loss to follow-up was as follows: 45 (23%) mother-infant 
pairs were lost to follow-up after Prevention of Mother-to-Child Transmission enrolment, 42 
(22%) after delivery and 108 (55%) during follow-up 51.   
The reasons for poor retention included poor maternal understanding of the importance of 
follow-up (n=59; 30%), infant death (n=54; 27%), lack of partner involvement (n=26; 13%) 
and change in residence (n=24; 12%) 51.  Fear of stigma (n=12; 6.1%) and maternal illness 
(n=6; 3.1%) accounted for a small proportion of the reasons for loss to follow-up 51.  In the 
multivariable model, incomplete antiretroviral prophylaxis in the mother or infant (AOR 1.9; 
95% CI: 1.1 to 3.4); infants who were breastfed for greater than six months (AOR 4.4; 95% 
CI: 2.0 to 9.7); and infants less than six months at the start of weaning (AOR 2.6; 95% CI: 
1.4 to 4.6) were significantly associated with loss to follow-up or death (p < 0.05) 51.  
Record of acute illness in the infants was negatively associated with loss to follow-up or 
death (AOR 0.3; 95% CI: 0.2 to 0.6; p< 0.05) 51.  Maternal and infant predictors of loss to 
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follow-up factors in this study were limited by the cross-sectional nature of the data 
collection, as the data may have been subject to recall bias 51.   
2.5.5 Benefits and Risks of Formula Feeding 
Exclusive formula feeding eliminates the risk of postpartum transmission of HIV from 
mother to infant in the postpartum period.  However, formula feeding can be negatively 
associated with infant morbidity and mortality, including increased risk of malnutrition and 
infectious diseases other than HIV 52-54. 
A randomised controlled trial conducted in antenatal clinics in Kenya involving 401 mother-
infant pairs showed that formula-fed infants, where mothers had access to potable water, 
had 40% less risk of HIV transmission compared to their breastfeeding counterparts 52.  
However, the two-year mortality risk in those breastfeeding was 24% (95% CI: 8% to 31%) 
versus 20.0% (95% CI: 14.4% to 25.6%; p = 0.30) in the formula-fed group 52.  During the 
first three months of life, formula-fed infants had an increased risk of diarrhoea and upper 
respiratory tract infection.  There were limitations to the comparability of the groups 
included the larger loss to follow-up in the formula group.  Mortality in the formula fed 
group may have been missed.  In addition, the analysis followed an intention to treat 
approach.  Those patients who were initially assigned to the formula group may not have 
adhered to exclusive formula feeding and may actually have breastfed 52.   
The paediatric diarrhoeal outbreak in Botswana in 2006 highlighted the importance of 
breastfeeding to child survival 55.  The morbidity and mortality in this outbreak occurred 
primarily in HIV-negative non-breastfeeding infants.  The HIV prevalence at the time of the 
outbreak was 33% 55.  Of the 153 infants hospitalized with diarrhoea, 97% were less than 
two years old and 88% were not breastfeeding.  Eighteen per cent of the children and 64% 
of the mothers were HIV-infected 55.  Only one breastfed infant under two years (1/16; 6%) 
died, compared to 24% (27/115) of children who were non-breastfed (relative risk 0.3; 95% 
CI: 0.1 to 1.9; p=0.19) 55.  The breastfeeding infant who died was also given formula milk 
and cow’s milk 55. 
A cohort study in Côte d’Ivoire found no significant difference between the formula feeding 
and exclusively breastfeeding groups in terms of rates of illness at 24 months 56.  Over the 
2-year follow-up, 37% of infants in the formula-fed group and 34% of infants in the 
breastfed group were free from any adverse health outcomes (hospitalisation or death or 
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validated diarrhoea or acute respiratory infection) (AHR 1.1; 95% CI: 0.8 – 1.9; p=0.44) 56.  
The study was conducted in an urban setting.  Women who chose to breastfeed 
exclusively were counselled to practice early cessation at 4 months of age 56.   
The benefits and risks of formula feeding should be contextualized by whether the living 
environment of mothers is supportive of her choice to formula feed 56-58.  According to the 
World Health Organisation in 2006, formula feeding should only be recommended as an 
alternative to breast milk to HIV-infected infants when it is affordable, feasible, acceptable, 
sustainable and safe (AFASS) 57, 58.  These criteria are rarely met in developing countries 
and mixed feeding is usually the practice.  The consequences for the infants of being 
exposed to the high risk of HIV transmission associated with breastfeeding combined with 
the risks of formula feeding are large.  The World Health Organisation recommendations 
on infant feeding in the context of HIV were revised in 2009 59.  These guidelines reflect 
new evidence regarding breastfeeding in the presence of antiretroviral interventions 60-64.  
The World Health Organisation now recommends that HIV-uninfected infants be 
exclusively breastfed for six months, followed by introduction of complementary foods and 
continued breastfeeding until one year of age 59.  The provision of breast milk should only 
be stopped once a nutritionally adequate, safe diet can be given to the infant 59. 
2.5.6 Benefits and Risks of Exclusive Breastfeeding 
Findings from the Breastfeeding and HIV International Transmission Study, a meta-
analysis of nine clinical trials, showed that the risk of continued HIV transmission through 
breastfeeding was related to the duration of breastfeeding 37.  The study described the 
cumulative probability risk of transmission as 1.6% at three months (95% CI: 0.3 to 2.9), 
4.2% at six months (95% CI: 1.8 to 6.7), 6.0% at nine months (95% CI: 3.3% to 8.6%), 
7.0% at 12 months (95% CI: 4.7% to 9.3%) and 9.3% at 18 months (95% CI: 3.8% to 
14.8%). This equates to about 1% risk of maternal to child transmission per month from 
exclusive breast-feeding 37. 
The most important benefit of exclusive breastfeeding is a reduction in infant morbidity and 
mortality in developing countries.  Babies who receive mixed feeds in their first month of 
life were more at risk of becoming infected with HIV than infants who were exclusively 
breastfed 65, 66.  
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A non-randomised intervention cohort study conducted in one urban, one semi-urban and 
seven rural antenatal clinics in KwaZulu-Natal determined the association between early 
infant feeding practices and the risk of HIV transmission and mortality at 18 months 66.  
The cohort of 1193 infants born between October 2001 and April 2005 to HIV-infected 
women was followed up until they were 18 months of age.  One hundred and forty-seven 
children died, of which 113 (77%) children were HIV-infected.  HIV-infection was 
diagnosed in 237 children.  The probability of death at 18 months for infants who were 
HIV-uninfected was 0.04 (95% CI: 0.03 to 0.06) and for HIV-infected 0.53 (95% CI: 0.46 to 
0.60).  The overall estimated HIV transmission risk exposure for breastfeeding during the 
18 months was 9.1 cases per 100 child-years of breastfeeding (95% CI: 5.8 to 12.5) 66.  
Furthermore, the study determined the association between infant feeding practices 
conducted at birth and the 18-month probability of death or acquiring HIV-infection 66.  An 
estimated 25% of exclusively breastfed infants born to women who were HIV-infected 
would have acquired HIV or died by 18 months compared to 20% of infants who were 
never breastfed (p=0.005) 66.  Infants who were breastfed beyond six months were 2.7 
times (95% CI: 1.2 to 6.0, p = 0.01) more likely to acquire HIV or die between seven and 
18 months compared to the groups who were either replacement fed, exclusively breastfed 
up to six months, or ceased all breastfeeding at any time point before six months 66.  The 
overall 18-month probability of survival for HIV-uninfected infants was not significantly 
different between the breastfed (n=800) and the replacement fed group (n=128).  Socio-
economic differences were described between mothers who breastfed for less than six 
months (n=136) with access to piped water inside their homes compared to mothers who 
continued to breastfeed beyond six months (n=688) (9.5% versus 7.7%, p=0.25).  The 
difference was not significant 66.   
Although the study showed similar 18-monthly mortality rate in breastfed and replacement 
fed HIV-uninfected infants, the results of the study should be placed into context of the 
environment in which the study was conducted 66.  Mothers were supported in both their 
choice and practice of infant feeding and received extensive counselling beyond the 
antenatal period 66.  Furthermore, women who chose to exclusively replacement feed were 
in a higher socio-economic class and could afford to do so hence the minimal mortality risk 
difference when compared to the exclusively breast fed group 66. 
A non-randomised intervention cohort study conducted in KwaZulu-Natal, South Africa 
showed an increased HIV-1 transmission risk associated with a maternal CD4+ count less 
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than 200 cells per mm3 (AOR 3.6; 95% CI: 2.0 to 6.4, p < 0.001) and birth weight less than 
2500 grams 54.  Most women given appropriate counselling chose to breastfeed (83%).  
Forty per cent of these women exclusively breastfed for six months 54.  Results from the 
Mashi Study in Botswana showed that although breastfeeding combined with zidovudine 
did not result in less vertical HIV transmission compared with formula feeding, the infant 
mortality at seven months was lower (9.3% versus 4.9%; p=0.003) 65.  The Mashi Study 
involved an intent-to-treat analysis and those patients initially assigned formula groups 
may have breastfed 65.  
Recent evidence from randomised controlled studies demonstrated that the use of 
(lifelong) antiretroviral therapy or antiretroviral prophylaxis provided to the mother or infant 
during breastfeeding reduces the risk of mother-to-child transmission 60-64.  Although these 
interventions have demonstrated HIV risk reduction in clinical trial settings, the 
effectiveness of these interventions were not assessed throughout the entire duration of 
breastfeeding or in operational settings.   
Breast milk contains immune factors that confer protection against infections and contain 
all the nutrient requirements the infant needs during the first six months of life.  A World 
Health Organisation meta-analysis of studies in developing countries showed that when 
diarrhoea and acute respiratory infection were the most common cause of death in infants, 
breastfeeding during the first six months of life provided measurable protection against 
these infections 67.  Breastfeeding also benefited the mother by suppressing ovulation 
thereby acting as an important method of contraception in developing countries.  
2.6 SUMMARY 
The literature reviewed in this chapter revealed that information related to the morbidity, 
mortality and loss to follow-up of HIV-exposed infants was lacking, particularly from study 





3 CHAPTER III: METHODS 
3.1 INTRODUCTION 
Whilst the level of prevention of mother-to-child transmission of HIV at McCord Hospital 
was comparable to developed countries, there was a paucity of data regarding the clinical 
outcomes of HIV-exposed infants in terms of morbidity, mortality, growth, and also about 
the number lost to follow-up care at the hospital.  This study explored the maternal 
demographic, socioeconomic, clinical and immunologic characteristics associated with 
loss to follow-up of infants in order to determine which mother-infant pairs were more likely 
to be lost to follow-up.  In this chapter, the type of research carried out and the study 
design applied is outlined.  In addition, the study population, sampling methods, data 
sources, statistical analysis, and bias and limitations of the study are described.   
3.2 TYPE OF RESEARCH 
This study was an epidemiological research study. 
3.3 STUDY DESIGN 
An observational, analytical retrospective cohort study design was used.   
3.4 STUDY SETTING 
The study was conducted at McCord Hospital, KwaZulu-Natal, South Africa.  
3.5 TARGET POPULATION 
The results of this study could be generalised to infants born to HIV-infected women who 
received antiretroviral prophylaxis and therapy during pregnancy in prevention of mother-
to-child transmission programmes in semi-private, urban settings in South Africa. 
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3.6 STUDY POPULATION 
Inclusion criteria6: HIV-infected women who received antiretroviral prophylaxis or therapy 
in the McCord Prevention of Mother-to-Child Transmission programme and either: 
1) Delivered their infants at McCord Hospital between 1 May 2008 and 31 May 2009; 
and/or  
2) Presented their infants for care to McCord Hospital, following delivery elsewhere, 
between 1 May 2008 and 31 May 2009.  
Exclusion criteria:  HIV-infected pregnant women who received antiretroviral prophylaxis or 
therapy from McCord Hospital Prevention of Mother-to-Child Transmission programme 
and who had stillbirth deliveries. 
3.7 SAMPLING 
3.7.1 Sampling method 
The period for inclusion in the study was 13 months7.  This allowed a minimum follow-up 
time of six months for infants born in May 2009 at the time of data abstraction.  
Convenience sampling was used8.  The records of a consecutive sample of all HIV-
infected women who received antiretroviral prophylaxis and treatment in the McCord 
                                                 
6
 The inclusion criteria for this study were narrow.  All HIV-infected mothers included in the study 
received either antiretroviral prophylaxis for prevention of mother-to-child transmission or 
antiretroviral therapy at McCord Hospital.  All infants included in the study were born from 1 May 
2008 to 31 May 2009 at either McCord Hospital or elsewhere.  If mothers met the study definition, 
but their infants were delivered elsewhere and were not brought back to McCord Hospital, these 
mother-infant pairs were not included in the study. 
7
 The study period was extended from 10 months to 13 months to ensure an adequate small 
sample size. 
8
 The follow-up clinic at McCord Hospital was established at the beginning of May 2008.  Prior to 
the inception of this clinic, follow-up data on HIV-exposed infants whose mothers received PMTCT 
or lifelong antiretroviral therapy was not available.  Given these limitations, and the narrow inclusion 
criteria for the study, the records of all mother-infant pairs meeting the inclusion criteria were 
selected from the Well Mother and Baby clinic database for the study.   
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Prevention of Mother-to-Child Transmission programme, and who delivered at McCord 
Hospital and/or presented their infants for care following delivery between 1 May 2008 and 
31 May 2009, were included in the study.   
3.7.2 Size of sample 
A biostatistician at the University of KwaZulu-Natal was consulted9.  The sample size was 
calculated based on the estimated prevalence of loss to follow-up of infants born to 
mothers in a Prevention of Mother-to-Child Transmission programme at McCord Hospital.  
A sample size of 256 infants with 95% confidence intervals was sufficient to provide 
precision of 6% based on the population estimate of loss to follow-up of 40%.  For the Cox 
proportional hazards model, at a 5% level of significance with power of 80% and 
withdrawal of 40%, the minimum number of events to for each category was 38.   
3.8 DATA SOURCES 
3.8.1 Measurement instruments/Data collection techniques 
The routine follow-up visits for infants born to HIV-infected women who attended the 
Prevention of Mother-to-Child Transmission programme at McCord Hospital were 
scheduled at one, six, ten, and 14 weeks, and thereafter at six, nine, 12, 15 and 18 
months.  
One-week visit 
The one-week visit was an enrolment visit to the Well Mother and Baby Clinic.  At this visit, 
mothers reported their method of feeding and the nurses weighed the infants and recorded 
their weight.  The head circumferences and lengths of the infants were not measured at 
the one-week visit.  
Follow-up visits 
At the follow-up visits, mothers reported their method of feeding and any illness episodes 
prior to the infant being brought to McCord Hospital.  Nurses at the Well Mother and Baby 
Clinic measured the weights, lengths and head circumferences of all infants.  A nurse or a 
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family practitioner conducted the general physical examination on infants.  This 
examination included an assessment of developmental milestones and growth of the 
infants.   
Laboratory tests 
Infants who tested HIV-infected at six or 14 weeks of age were confirmed with a repeat 
DNA polymerase chain reaction assay.  All infants who tested negative for HIV-infection 
were tested for HIV at 18 months using two HIV Elisa antibody tests.  All infants who were 
confirmed as HIV-infected at six weeks, 14 weeks or 18 months of age were referred to a 
paediatrician at McCord Hospital.   
3.8.1.1 Data abstraction 
Study data were abstracted from paper and electronic sources.  The primary source of 
data were paper records. The sources are described below: 
i. Paper sources 
Maternal data 
Routine data on antenatal history, care, treatment and delivery were collected from 
maternal records recorded by clinicians, usually family practitioners.  The following 
variables were collected: 
• maternal socio-demographic details; 
• maternal diagnosis of HIV; 
• enrolment in the Prevention of Mother-to-Child Transmission programme; 
• antiretroviral prophylaxis or treatment taken during pregnancy; 
• antenatal enrolment: height, weight, parity, previous pregnancies, prior 
complications in pregnancy and delivery, and pre-existing conditions; 
• antenatal illness episodes; 
• date, mode and complications during delivery , and  




Clinical data on infants were collected from the infants’ clinical record files.  Nurses 
or family practitioners recorded all clinical data on infants.  These standard custom-
developed clinical record forms were developed by the researcher and were 
implemented at the inception of the Well Mother and Baby Clinic at McCord 
Hospital in May 2008 (Appendix B).  The following data were collected from the 
infant charts: 
• illness events prior to attendance at McCord Hospital;  
• feeding history;  
• immunization history; 
• current illness events; and 
• physical examination of the infant (Appendix B).    
ii Electronic source 
Maternal data 
Prevention of Mother-to-Child Transmission programme staff also routinely entered 
clinical and personal data about HIV-infected mothers into an electronic database 
(Trakcare)10.  The following data were entered into the database: 
• diagnosis of maternal HIV; 
• laboratory results including CD4+ per cent and CD4 + count, plasma 
RNA viral load,  
• maternal antiretroviral regimen dispensed to women during their 
pregnancy and previous antiretroviral regimen prescribed if any; 
• follow-up: illnesses during pregnancy,  
• date and mode of delivery and complications 
                                                 
10
 Certain cadres of nurses and counsellors and all clinicians (general and specialists) in the 
Prevention of Mother-to-Child Transmission programme and the Obstetric and Gynaecology 
department at McCord Hospital routinely entered clinical data about pregnant women into Trakcare.  






The routine capturing of data on infants were not well established, and limited data 
on infants were available from this electronic source.  The electronic database was 
primarily used for the following purposes: 
• verify dates of the infant visits to McCord Hospital; 
• verify infant HIV-test results (six-weeks, ten-weeks, 14-weeks and 18-
months); and 
• track the location of infant files. 
3.8.1.2 Data handling 
Data for the study, accessed from various sources, were extracted to a specific study data-
collation form by the researcher, a trained research assistant and a medical student 
(Appendix C).  The data was then single-entered into a database (Microsoft Access 2007) 
by one data capturer.  Data was cleaned and processed (descriptive and analytic 
statistics) by the researcher alone under the guidance of a biostatistician.  The researcher 
exported data on illness events from the Access database to Microsoft Excel 2007.  The 
researcher assigned each type of illness event a unique code, the events were filtered and 
sorted based on their codes and the dates of the events.  The researcher then cleaned the 
illness events to ensure that there were no overlapping events.  Preceding illness events 
overlapping or within a few days of the current illness events were excluded.  Each type of 
illness event was exported to Stata/IC version 11 (Statacorp, College Station, Texas) and 
assigned as failure variables to derive incidence rates. 
3.9 VARIABLES 
Exposure variables were as follows: 
• Maternal age; 
• Marital status; 
• Race; 
• Employment status; 




• Maternal anthropometry: weight (kg) and height (cm); 
• Maternal illness antenatally; 
• Maternal CD4+ count and viral load; 
• Maternal antiretroviral regimen; 
• Mode of delivery; 
• Parity; 
• Infant antiretroviral prophylaxis; 
• Infant cotrimoxazole prophylaxis; and 
• Infant birth weight. 
The infant clinical outcome variables included: 
• Upper respiratory tract infections; 
• Lower respiratory tract infections; 
• Skin and mucous membrane infections; 
• Gastrointestinal infections; 
• Hospital admissions; 
• Other (infections not meeting the criteria for the above categories); 
• Loss to follow-up of infants following delivery; and 
• Feeding practice (exclusive breastfeeding, exclusive formula feeding, mixed 
feeding). 
3.9.1 Reliability and Validity of Data Source 
The principal investigator spent seven months at McCord Hospital from December 2007 
until June 2008.  During that time, data collection techniques were implemented for routine 
clinical care.  There were regular reviews of all maternal and infant records with all 
relevant staff during the first six months of the inception of the Well Mother and Baby Clinic 
at McCord Hospital to ensure that the records were complete in terms of history, 
investigation and clinical data.  A monitoring and evaluation officer at McCord Hospital 
verified that the clinical information captured on the patient records and Trakcare database 
at the Well Mother and Baby Clinic was accurate.   
Data on the antiretroviral therapy prescribed to women in the Prevention of Mother-to-
Child Transmission programme were extracted from the peri-partum maternal record and 
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were verified from pharmacy records on the Trakcare database.  Similarly, maternal 
antenatal baseline CD4+ cell counts and viral loads were collected from records of 
laboratory results in the mothers’ files and verified from laboratory records on Trakcare.   
The clinician estimated the gestational age of the foetus at the mothers’ first antenatal 
booking visit.  In some instances, gestational age was verified by an early ultrasound scan.   
A research assistant and a medical student were recruited to assist with data collection.  
The researcher trained the data capturers to conduct data entry.  Both the research 
assistant and the medical student were familiar with the variables collected for the study.  
Data collection were initially conducted in the presence of the researcher in order to clarify 
definitions, the data collection tool and the data collection process.  The researcher 
undertook the majority of the data collection.  It was not possible to validate the clinical 
diagnoses recorded in the patient records and may have resulted in non-differential 
misclassification bias.   
Prior to data abstraction, a code book with specific definitions for all data elements was 
prepared as part of the operational guidelines. The Microsoft Access database had built-in 
checks and validation rules, hence only accept legal values were accepted during data 
entry.  Once data entry were completed, the researcher conducted descriptive statistics to 
detect outliers.  The researcher checked missing or erroneous data against patient 
records.  The researcher also clarified any discrepancies in data with clinic staff.  Due to 
logistic and time constraints, the researcher did not conduct double entry of data, which 
would have increased the validity of the study. 
3.10 BIAS AND LIMITATIONS 
3.10.1 Selection bias 
The potential for selection bias was minimised by using charts of all mothers and infants 
enrolled at McCord Hospital during the study period. 
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3.10.2 Information bias 
The variation11 in the quality and consistency of data may result from differences in the 
human resources at McCord Hospital since 2008. However, the potential for information 
bias is minimal as data collection practices were standardised since the opening of the 
Well Mother and Baby Clinic in May 2008.  The researcher-collected data on clinical 
outcomes of infants based on the availability of routine data, and may have resulted in 
misclassification information bias.  Loss to follow-up forms was included in charts of infants 
who did not return to the clinic.  Clinic staff attempted to contact caregivers to determine 
the reason for loss to follow-up.  However, in most instances the reason for loss to follow-
up was not determined and contributed to the information bias in the study.  Data were not 
double entered and could have introduced information bias.  The researcher cleaned the 
data and verified missing data by inspecting patient files.  Exploratory data analysis were 
used to assess the study for outlying data and these errors were verified and corrected.  
The database was developed using validation rules to ensure the plausibility of data 
entered. 
3.10.3 External generalisability 
McCord Hospital is semi-private.  The hospital is state-aided but funding is subsidised by 
private donors and patient fees. The socio-demographic characteristics of the population 
might differ from that of the general public and the results of the research may not be 
generalisable to the public HIV-infected antenatal population of South Africa. 
3.10.4 Confounders 
Each independent variable may act as a confounder when assessing the effect of each 
independent variable on the dependent variable in the bivariate analysis.  These 
confounders were adjusted for by using multivariable analysis to control for confounding 
effects.  No interactions were considered in the analysis of loss to follow-up of infants or 
upper respiratory illness.  There may be confounding effects due to variables not assessed 
in the study.  These variables may include maternal area of residence, maternal education 
level, maternal disclosure of HIV status, the number of persons living in the household, 
                                                 
11
 Both general medical practitioners and nurses examined infants at the McCord Hospital Well 
Mother and Baby Clinic.  There may be variation in history taking, physical examination and clinical 
diagnoses of the infants. 
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infant anaemia and paternal factors such as living in the household, occupational status 
and level of education.   
3.11 STATISTICAL ANALYSIS 
3.11.1 Descriptive methods 
Data were abstracted to Microsoft Access 2007 database, and thereafter imported into 
Microsoft Excel and SPSS version 15.0 (SPSS, Chicago, Illinois) for cleaning and basic 
frequency measures. 
The characteristics of the study population, and outcomes in terms of morbidity, mortality, 
infant feeding and loss to follow-up of infants were measured using descriptive statistics.  
Frequencies and proportions were calculated to describe the data, and then presented in 
the form of frequency distribution tables.  Ninety-five per cent confidence intervals (95% 
CI) were calculated using the exact binomial method.   
3.11.2  Analytical methods 
Morbidity events, HIV transmission, child deaths and loss to follow-up of infants were 
treated as time-to-event variables and were analyzed with Kaplan-Meier methods 68.  
Frequencies of infections (excluding HIV) were calculated according to the age at the initial 
diagnosis; early neonatal (zero to six days), late neonatal (seven to 27 days), or post 
neonatal (greater or equal to 28 days).  In addition, the cumulative rate of infections were 
calculated using Poisson regression to count outcomes 68.   
Predictors of initial diagnosis of infant upper respiratory illness were explored as slightly 
more than half of the infants had experienced at least one upper respiratory event.  
Furthermore, most cases of upper respiratory infection were likely to be incident events.  
Although skin and mucous membrane infections were also common, this outcome was not 
considered further, as some cases of skin infections were likely to be chronic.  It was 
therefore not possible to separate incident and prevalent cases of skin and mucous 
membrane infections.   
In addition, predictors of loss to follow-up of infants were examined.  Socio-demographic, 
clinical, immunological and biological (maternal, obstetric, perinatal and infant) factors 
were assessed to determine their association with loss to follow-up of infants.   
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Similar analyses were conducted to determine predictors of infant upper respiratory illness 
and loss to follow-up of infants.  The proportional hazards-assumption of the Cox 
regression model was assessed with the Nelson-Aalen estimate in exposed and 
unexposed groups 68.  Associations between categorical variables with upper respiratory 
tract infections were evaluated by using the Pearson’s chi square tests 68.  Cox 
proportional hazards regression analysis were used to retrieve baseline survival function 
and to model multivariate survival data 68.  The likelihood ratio test was used to assess the 
fit of the model 68.  For multiple regressions, a backward elimination procedure used log-
likelihood criteria with p > 0.1 for removing variables and p < 0.05 for entering variables 68.   
The researcher performed all descriptive and analytic statistics.  All analyses were 
performed in SPSS version 15 (Chicago, Illinois) and Stata/IC version 11 (Statacorp, 
College Station, Texas). 
3.12 ETHICS 
Ethical approval for this study was obtained from University of KwaZulu-Natal Biomedical 
Research Ethics Committee (BE160/08) (Appendix A) as well as McCord Hospital 
Research Ethics Committee (Appendix A).  
Individuals were not consented for participation in this retrospective chart review study. 
The reasons for this were as follows: (i) no patient identifiers were collected in this study; 
(ii) no patient contact was necessary; (iii) data used for the study included only data 
collected as per standard care at McCord Hospital.  It should also be noted that women 
who enrolled to the Prevention of Mother-to-Child Transmission programme gave their 
consent for their and their child’s data to be used for programmatic evaluation purposes.  
3.12.1 Permissions 
Permission to use the routine data collected for the secondary analysis was obtained from 
the Superintendent of McCord Hospital, Dr H. Holst. The study was registered as a 
research project (PGR008/08) (Appendix A) for the Master of Medicine (Public Health 
Medicine) with the Postgraduate Education Committee of the Nelson R. Mandela School of 




This epidemiological study used a retrospective cohort design.  The purpose of the study 
was to measure the clinical and loss to follow-up outcomes of infants, born to HIV-infected 
women who attended the Prevention of Mother-to-Child Transmission programme at 
McCord Hospital, and assessed predictors of loss to follow-up of infants.  In this chapter 
the study population, study sampling methods, data sources and biases and limitations 
were described.  
38 
 
4 CHAPTER IV: RESULTS 
4.1 INTRODUCTION 
The purpose of this retrospective cohort study was to measure the clinical, loss to follow-
up and feeding outcomes of HIV-exposed infants at McCord Hospital.  Furthermore, the 
study aimed to assess maternal demographic, socio-economic, clinical and immunological 
characteristics associated with loss to follow-up of infants.  The study population 
comprised of infants, born to HIV-infected mothers who received antiretroviral prophylaxis 
and treatment in the McCord Prevention of Mother-to-Child Transmission programme, and 
who delivered at McCord Hospital and/ or presented their infants to McCord Hospital for 
care following delivery between 1 May 2008 and 31 May 2009. 
4.2 STUDY SAMPLE 
In total, 272 mothers presented to McCord Hospital for care between 1 May 2008 and 31 
May 2009.  Fourteen infants were excluded from the study for reasons that included 
records not being found, infants not meeting the inclusion criteria and stillbirths (Figure 1).  
There were 258 deliveries resulting in 265 infants (252 singletons, five sets of twins and 
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(n=14) 
258 mothers with 
258 deliveries 
Figure 1: Study sample of infants born to HIV-infected mothers in the Prevention of Mother-to-
Child Transmission programme at McCord Hospital, 1 May 2008 to 31 May 2009 
Died  
(5/265) (1.9%) infants  
Lost to follow-up  
(105/260) (40.4%) infants 
Remained in care at McCord Hospital  




4.3 PRESENTATION OF DATA 
4.3.1 Characteristics of the study population at McCord Hospital 
Socio-economic, demographic and other characteristics of the infected mothers was 
summarised (Table 1).  The median maternal age was 28.0 years (IQR: 15.0 to 45.0 
years).  The race of only 125 (48.4%) mothers was recorded 12.  The majority (n=119, 
95.2%) of women were Black (South Africans).  Most (n= 214, 84.9%) mothers attending 
McCord Hospital were single and almost two-thirds (n=165, 65.7%) were employed.   
Smoking, alcohol consumption and illicit drug use by the mothers was reported to be 
uncommon during pregnancy.  The mean maternal parity prior to this pregnancy was 1.0 
live births (IQR: 0 to 5).  Most infants (n=163, 64.1%) were delivered by caesarean section.  
An obstetric emergency was given as the reason for the delivery requiring surgical 
intervention in 74 (29.1%) women with the rest being elective caesarean sections.  Of the 
89 elective caesarean sections, 57.3% (n=51) were indicated for maternal HIV to prevent 
mother-to-child transmission.  Only 11.8% (n=29) of pregnant women presented for their 
first antenatal visit early, (before 12 weeks of gestation), and 25.2% (n=62) of patients 
booked late in their third trimester.   
The clinical, immunological, and virologic disease characteristics were collected at the first 
antenatal visit. The baseline median maternal CD4+ cell count was 308 cells/mm3 (IQR: 17 
to 962 cells/mm3) and median viral load 4320 copies/ml (IQR: 25 to 1 810 000 copies/ml).  
Only 27 (10.5%) women had the WHO staging of their disease recorded at baseline.   
Approximately half (n=127, 51.4%) of the mothers reported an illness event during the 
antenatal period.  Approximately 12 mothers (9.4%) had pulmonary tuberculosis and were 
receiving anti-tuberculosis treatment.  There was only one maternal death (0.4%) during 
the study period.  The cause of the maternal death was reported as disseminated Kaposi’s 
Sarcoma. 
Less than half (n=123, 47.7%) of women were already on antiretroviral therapy at their first 
pregnancy visit.  Of these 123 women, 36 (29.3%) women were commenced on 
                                                 
12
 Race was not routinely collected during the first six months at the McCord Hospital Well Mother 
and Baby clinic 
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antiretroviral therapy prior to their pregnancies, and 68 women (55.3%) were initiated on 
triple antiretroviral therapy in their current pregnancies.  Approximately 15.4% (n=19) of 
women were commenced on triple antiretroviral therapy for prevention of mother-to-child 
transmission as their viral loads were greater than 1500 copies/ml13 and were included in 
the category HAART for life..  There were 52.3% (n=135) of women on antiretroviral 
prophylaxis for prevention of mother-to-child transmission.  
                                                 
13
 Women who had CD4
+
 counts >200 cells/mm
3
 but viral loads > 1500 copies/ml were prescribed 
triple antiretroviral therapy for prevention of mother-to-child transmission.  These regimens were 
discontinued after delivery of their infants; thereafter the women were initiated on seven days of 
zidovudine and lamivudine to prevent the development of resistance to antiretroviral drugs.   
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Table 1: Characteristics of HIV-infected women who attended the Prevention of 
Mother-to-Child Transmission programme at McCord Hospital, and whose infants 
were born from 1 May 2008 to 31 May 2009 
Maternal characteristics N* n* % 95%  
Confidence 
Intervals 
Maternal age, yrs     
Mean (median) 255 28.5 
(28.0) 
 27.8 – 29.2 
≥ 30   107 42.0 35.8 - 48.3 
< 30   148 58.0 51.7 - 64.2 
Race 125    
Black (South African)  119 95.2 89.8 - 98.2 
Asian  4 3.2 0.9 - 8.0 
White  1 0.8 0.0 - 4.4 
Black (other African)  1 0.8 0.0 - 4.4 
Employed 251    
Yes  165 65.7 59.5 - 71.6 
No  86 34.3 28.4 -  40.5  
Marital status 252    
Single  214 84.9 79.9 - 89.1 
Married  38 15.1 10.9 - 20.1 
Parity 247    
Primiparity  86 34.8 28.9 - 41.1 
Multiparity  161 65.2 58.9 - 71.1 
Maternal CD4+ count 
(cells/mm3) 
250    
< 200   68 27.2 21.8 - 33.2 
200 – 499  147 58.8 52.4 - 65.0 
≥ 500  35 14 9.9 - 18.9 
Maternal viral load (copies/ml) 224    
<1000  70 31.2 25.2 - 37.8 
1000 - 9999  77 34.4 28.2 - 41.0 
≥ 10 000  77 34.4 28.2 - 41.0 
Maternal antiretroviral regimen 258    
HAART for life  123 47.7 41.4 - 54.0 
AZT+3TC from 28 weeks  76 29.5 24.0 - 35.4 
AZT from 28 weeks  38 14.7 10.6 - 19.7 
NVP only  7 2.7 1.1 - 5.5 




Table 1 (contd.) 
Maternal characteristics N* n % 95%  
Confidence 
Interval 
Booking gestational age, 
weeks 
246    
0-12  29 11.8 8.0 - 16.5 
13-27  155 63.0 56.6 - 69.1 
≥ 28   62 25.2 19.9 - 31.1 
Any illness during 
pregnancy 
247    
Yes  127 51.4 45.0 – 57.8 
No  120 48.6 42.2 – 55.0 
Pulmonary tuberculosis 127 12 9.4 5.0  -15.9 
Mode of delivery 254    
Emergency C/S  74 29.1 23.6 - 35.1 
Booked C/S  89 35.0 29.2 - 41.3 
NVD  91 35.8 29.9 - 42.1 
Maternal mortality 256    
No  255 99.6 97.8 – 100 
Yes   1 0.4 0.0 - 2.2 
N* the number of mothers across categories of maternal characteristics may not add up to 258 due 
to missing data.   
The median length of infant follow-up at McCord Hospital in this study was 9.1 months 
(absolute range: 1 day to 21 months) (Table 2).  Median birth weight was 3080 grams 
(IQR: 980 to 4500) and 32 (12.8%; 95% CI: 8.9% to 17.6%) infants were of low birth 
weight (<2.500 grams).   The median gestational age at birth was 38 weeks (IQR: 30 to 
42) and 189 infants were born at term at or after 37 weeks (89.2%, 95% CI: 84.2% to 
93.0%) (Table 2).  Approximately 223 (98.7%, 95% CI: 96.2% to 99.7%) infants received 
nevirapine and zidovudine as antiretroviral prophylaxis following delivery (Table 2).  Of the 
265 infants in the cohort, 13 (4.9%) were followed-up for 18 months and were discharged 
from the clinic14.  Vaccination coverage for Bacillus Calmette Guérin (BCG) and oral polio 
                                                 
14
 The Well Mother and Baby Clinic at McCord Hospital routinely follow-up until infants from birth to 




vaccine (OPV) was 83.0% (95% CI: 77.9% to 87.3%) at birth (Table 2).  By six weeks of 
age, vaccine coverage for diphtheria, pertussis and tetanus (DPT), and Haemophilus 
influenzae type B (HiB) vaccine fell to 79.2% (Table 2).  Vaccine coverage for Hepatitis B 
at six weeks was 76.2% (Table 2), as the vaccination was out of stock and some infants 
were not vaccinated with Hepatitis B at this visit.   By nine months of age, only 53.5% of 
infants requiring measles were vaccinated at McCord Hospital and measles coverage 
diminished further to 27.1% (95% CI: 15.3 to 41.8) by 18 months of age.15 
                                                 
15
 Pneumococcal and rotavirus vaccination commenced in November 2008 at McCord Hospital.  
Data on these vaccinations were inconsistently recorded in infant medical records and was 




Table 2: Characteristics of infants born to HIV-infected women in the Prevention of 
Mother-to-Child Transmission programme at McCord Hospital, from 1 May 2008 to 
31 May 2009.  
Infant characteristics N* n* % 95% Confidence 
Interval 
Observed length of follow-up     
Mean (median), months  7.9 (9.1)  7.2 – 8.6 
Sex 252    
Male  122 48.4 42.1 - 54.8 
Female  130 51.6 45.2 - 57.9 
ARV prophylaxis at birth 226    
Nevirapine and zidovudine  223 98.7 96.2 - 99.7 
Gestational age at delivery, 
weeks 
212    
Mean (median)  38.2 
(38.0) 
 37.8 – 38.2 
< 37  23 10.8 7.0 - 15.8 
≥ 37  189 89.2 84.2 - 93.0 
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Table 2 cont 
Infant characteristics N* n* % 95% Confidence 
Interval 
Vaccination coverage     
Birth 265    
BCG  220 83.0 77.9 – 87.3 
OPV  220 83.0 77.9 – 87.3 
6 week 265    
DPT and HiB  210 79.2 73.9 – 84.0 
OPV  210 79.2 73.9 – 84.0 
Hepatitis B  202 76.2 70.6 – 81.2 
10 week 265    
DPT and HiB  189 71.3 65.5 – 76.7 
OPV  189 71.3 65.5 – 76.7 
Hepatitis B  180 67.9 61.9 – 73.5 
14 week 265    
DPT and HiB  181 63.8 62.3 – 73.9 
OPV  181 63.8 62.3 – 73.9 




Measles, OPV and DPT 














47.0 – 59.8 
 
15.3 – 41.8 
Mean (median) 250 3052.3 
(3080) 
 3000.3 – 3139.7 
< 2500  32 12.8 8.9 – 17.6 
≥ 2500  218 87.2 82.4 – 91.1 




4.3.2 Proportion of infants by feeding category at birth 
The majority of the 265 infants in the study were reported to be exclusively formula-fed at 
birth (97.5%; 95% CI: 94.7% to 99.1%) (Table 3).  The median duration of exclusive 
breastfeeding was 18.5 weeks, slightly longer than the median duration of exclusive 
formula feeding at 13.0 weeks.   
Table 3: Type and length of exclusive infant feeding methods reported by HIV-
infected women in the Prevention of Mother-to-Child Transmission programme at 
McCord Hospital, following delivery of their infants from 1 May 2008 to 31 May 2009 
Feeding 
category 







formula feeding  
235 97.5 94.7 - 99.1 13.0 
Exclusive breast 
feeding 
6 2.5 0.9 - 5.3 18.5 
n* does not add up to 265 due to missing data on reported feeding methods 
4.3.3 Clinical outcomes of infants 
4.3.3.1 Types of infections 
Overall, 177 infants (N=265, 66.7%) were reported to have suffered 542 infections from 
birth to 18 months (3.3 infections per infant).  The most frequent infections involved the 
upper respiratory tract (51.2%) and skin and mucous membrane infections (30.9%) (Table 
4).  Two hundred and eighty infections of the upper respiratory tract occurred in 136 of 265 
(51.3%) infants.  Cumulatively, the incidence rate of upper respiratory infections was 0.44 
cases per 100 child-weeks of follow-up (95% CI: 0.39 to 0.49).  More than one-third (n=98, 
37.0%) of infants had skin and mucous membrane infections.  Infections of the 
gastrointestinal tract were less common with only 50 infants (18.9%) acquiring an infection.  
Other infrequent infections were of the lower respiratory tract (n=18, 6.8%).   
In terms of lower respiratory tract infection, one infant was presumed HIV-infected.  Two 
infants were diagnosed with pulmonary tuberculosis (0.8%) at approximately three months 
of age.  The mothers of both these infants were diagnosed with pulmonary tuberculosis in 
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their pregnancies.  The receipt of isoniazid prophylaxis16 was inconsistently recorded in the 
study and it was unclear if these infants received prophylaxis.   
Table 4: Number and types of infections in infants born to HIV-infected women who 
attended the Prevention of Mother-to-Child Transmission programme at McCord 
Hospital, from 1 May 2008 to 31 May 2009 
Diagnostic category n (%)  
of infants 
Number (%)  
of infections 
Upper respiratory tract  136 (51.3) 280 (51.2) 
Gastrointestinal 50 (18.9) 67 (12.2) 
Skin, mucous membrane 98 (37.0) 169 (30.9) 
Lower respiratory tract 18 (6.8) 22 (4.2) 
Other** 4 (1.5) 4 (0.7) 
N = 265 infants 
Other** infections comprised two cases of chicken pox, one case of febrile seizures, and one case 
of urinary tract infection. 
4.3.3.2 Age at initial diagnosis of infection 
The types of infection and the time to first diagnosis to each infection were recorded (Table 
5).  The initial diagnosis of upper respiratory (n=48, 35.3%), lower respiratory (n=7, 
38.9%), and skin and mucous membrane infections (n=37; 37.8%) was most common 
from 61 to 120 days.   
The incidence rate of upper respiratory tract infections was 2.5 cases per 100 child-weeks 
(95% CI: 2.1 to 2.9 infections per 100 child-weeks) (Table 5).  The proportion of upper 
respiratory tract infections decreased after 240 days with 26 (19.1%) cases occurring 
during this period. 
Unexpectedly, gastrointestinal infections were infrequent with an incidence rate of 0.6 
cases per 100 child-weeks (95% CI: 0.5 to 0.8 per 100 child-weeks) (Table 5).  In contrast 
to skin and mucous membrane and upper respiratory tract infections, the majority of 
gastrointestinal infections occurred after 240 days (n=33, 66.0%).   
                                                 
16
 Twelve HIV-infected pregnant women were diagnosed with pulmonary tuberculosis and received 
anti-tuberculosis medication – two infants were recorded as receiving isoniazid prophylaxis.   
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Lower respiratory tract infections were least common with an incidence rate of 0.2 cases 
per 100 child-weeks of observation (95% CI: 0.1 to 0.3 cases per 100 child-weeks) (Table 
5).     
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Table 5: Number and percent of types of infections, age of onset to first infection, and incidence rate of infections for infants born to HIV-
infected women attending the Prevention of Mother-to-Child Transmission programme at McCord Hospital, 1 May 2008 to 31 May 2009 
 









28 – 60 
days 




>240 d n Incidence rate of 
infections per 100 child-




0 (0)  
 
7 (5.1)  
 
23 (16.9) 48 (35.3)  
 
32 (23.5) 26 
(19.1)  
136 
2.5 (2.1 - 2.9) 
Skin, mucous 
membrane 




31 (31.6) 37 (37.8) 15 (15.3) 12 
(12.2) 
98 1.6 (1.3 - 1.9) 






2 (4.0) 8 (16.0) 33 
(66.0) 
50 0.6 (0.5 - 0.8) 
Lower respiratory 
tract 






7 (38.9) 4 (22.2)  5 
(27.8)  
18 0.2 (0.1 - 0.3) 
N = 265 infants 
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4.3.3.3 Factors associated with URTI 
Cox proportional hazards regression analysis was conducted to quantify any associations 
between the maternal and infant exposures and first upper respiratory tract event in 
infants17 (Table 6).  Only first-born infants18 from multiple births were included in the 
analysis (n=7). Exposure variables from the unadjusted analyses were included in the 
multivariable analyses if the test for heterogeneity showed that the risk factor was 
significant19.  
Maternal socio-demographic, clinical, immunologic, virologic and infant exposure variables 
were explored to determine their association with upper respiratory events in infants.  In 
the adjusted analyses, infants born to mothers younger than 30 years old at the time of 
delivery had a 10% greater risk of their infant experiencing an upper respiratory event 
relative to infants with older mothers but the association was not statistically significant 
(AHR 1.1; 95% CI: 0.7 to 1.8; p = 0.655).  Infants of single mothers had a 50% increased 
risk of illness compared to married mothers, but this was also not statistically significant 
(AHR 1.5; 95% CI: 0.9 to 2.8; p = 0.136).   
There was no significant association between maternal illness during pregnancy and 
infantile upper respiratory infection (AHR 1.3; 95% CI: 0.9 to 2.0; p = 0.167).  The use of 
zidovudine (AHR 0.5; 95% CI: 0.0 to 4.7; p= 0.506), zidovudine and lamivudine (AHR 1.2; 
95% CI: 0.1 to 11.1; p = 0.902) and triple antiretroviral therapy (AHR 1.3; 95% CI: 0.1 to 
                                                 
17
 The Cox proportional hazards regression analysis was conducted by myself after consultation 
with Ms Tonya Esterhuizen, a biostatistician, who taught me how to conduct the analysis. 
18
 Only first-born infants were included in the analyses as a population-based study showed that 
second born twins were at greater risk for neonatal morbidity and mortality (Shinwell 2004).  The 
inclusion of second-born and third born infants of multiple births may have overestimated the 
association between exposure variables and first upper respiratory tract event. 
19
 Cox proportional hazards regression analysis was used to retrieve baseline survival function and 
to model multivariate survival data.  The log-likelihood ratio was used to determine the fit of the 
model.  For multiple regressions, a backward elimination procedure used log-likelihood criteria with 




12.8; p = 0.81) during pregnancy was not found to be statistically significant in the 
development of upper respiratory tract illness in infants.   
With respect to maternal immunologic and virologic characteristics, only maternal viral load 
predicted infantile upper respiratory infection.  Maternal CD4+ counts between 200 to 499 
cells/mm3 (AHR 1.6; 95% CI: 0.9 to 2.6; p = 0.085) and ≥ 500 cells mm3  (AHR 2.1; 95% 
CI: 0.9 to 4.5; 95% CI: 0.069) were associated with infant upper respiratory illness in both 
the crude models.  This finding of increased risk of infantile upper respiratory illness and 
high maternal CD4+ count may be due to random error and was not found to be significant 
in the adjusted model.  An association was observed between maternal viral load and 
infant upper respiratory infection.  In the adjusted model, infants of mothers with viral load 
from 1000 to less than 10 000 copies/ml had a 40% greater risk of an upper respiratory 
event (95% CI: 0.8 to 2.4; p = 0.280) compared to mothers with low viral loads but the 
association was not significant.  The risk of infection increased as viral load increased to 
10 000 copies/ml and above and was shown to be statistically significant (95% CI: 1.0 to 
3.3; p = 0.039).   
Other significant risk factors for infantile upper respiratory illness were the gestational age 
at delivery and the use of infant cotrimoxazole prophylaxis20.  In the adjusted analysis, 
compared to infants born at term (≥ 37 weeks), infants who were less than 37 weeks of 
gestation at birth (n=22) were 2.7 times more likely to experience an upper respiratory 
illness event (95% CI: 1.4 to 5.3, p= 0.002).  Infants who were prescribed cotrimoxazole 
prophylaxis at six weeks of age were 2.2 times more likely to experience an upper 
respiratory event (95% CI: 1.2 to 3.9; p = 0.011) compared to infants who were not on 
prophylaxis.   
Maternal parity was found to be a risk factor for infantile upper respiratory illness but this 
association was not statistically significant after adjustment for confounders (AHR 1.2; 95 
CI: 0.7 to 1.9; p = 0.497).  Compared to emergency caesarean section, elective caesarean 
delivery (AHR 1.3; 95% CI: 0.8 to 2.2; p = 0.217) and normal vaginal delivery (AHR 1.3; 
95% CI: 0.8 to 2.1, p= 0.234) increased the risk of infantile upper respiratory illness but the 
association was also not statistically significant  
                                                 
20
 Infants were prescribed cotrimoxazole prophylaxis from six weeks of age until DNA polymerase 
chain reaction assays diagnosed the infants as HIV-uninfected. 
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Infant exposures that were not significant risk factors for upper respiratory illness were the 
sex of infants (AHR 0.7; 95% CI: 0.5 to 1.1; p = 0.131), weight at birth (AHR 1.3; 95% CI: 
0.7 – 2.5; p = 0.359), and loss to follow-up of infants (AHR 1.2; 95% CI: 0.7 to 2.0; p = 
0.496).  These exposure variables remained in the model as potential confounders. 
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Table 6: Cox regression analysis of risk factors associated with first onset of upper respiratory tract infection in 
infants born to mothers in a Prevention of Mother-to-Child Transmission programme at McCord Hospital, 1 May 2008 
to 31 May 2009 
Characteristic N* n %  Unadjusted hazard  
ratio  
(95% CI) 





Maternal age        
≥30 years 107 54 50.5 1.0  1.0  
< 30 years 148 76 51.4 1.3 0.175 1.1 0.655 
    (0.9 – 1.8)  (0.7 – 1.8)  
Marital status        
Married 38 16 42.1 1.0  1.0  
Single 214 114 53.3 1.6 0.069 1.5 0.136 
    (1.0 - 2.7)  (0.9– 2.8)  
Alcohol use        
No 249 126 50.6 1.0  1.0  
Yes 2 1 50 1.1 0.909 0.9 0.951 
    (0.2 – 8.0)  (0.1 – 7.4)  
Any antenatal maternal illness        
No 120 55 45.8 1.0  1.0  
Yes 127 73 57.5 6.4 




(0.9 – 2.0) 
0.167 
N* 258 infants were included in the Cox regression model after exclusion of second does add up to 258 due to missing data 
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Table 6 (contd.) 
Characteristic N n % 
Unadjusted hazards ratio  
(95% CI) p-value 
Adjusted 
hazards ratio 
(95% CI) p-value 
Maternal CD4+  count, cells/mm3 
< 200  68 39 57.4 1.0 1.0 
200 – 499 147 75 51.0 1.0 0.852 1.6 0.085 
(0.7 – 1.5) (0.9 - 2.6) 
≥ 500 35 17 48.6 1.1 0.743 2.1 0.069 
 
(0.6 – 2.0) (0.9 – 4.5) 
Viral load, copies/ml21 
< 1000 70 36 51.4 1.0 1.0 
1000 - < 10 000 77 37 48.1 1.1 0.66 1.4 0.28 
(0.7 – 1.8) (0.8 – 2.4) 
≥ 10 000 77 43 55.8 1.4 0.142 1.9 0.039 
 
(0.9 – 2.2) (1.0 – 3.3) 
Maternal antiretroviral regimen 
Nevirapine only 6 1 16.7 1.0 1.0 
Zidovudine from 28 weeks 38 17 44.7 2.3 0.428 0.5 0.506 
(0.3 – 17.1) (0.0 – 4.7) 
Zidovudine/ lamivudine from 28 weeks 76 37 48.7 4.3 0.149 1.2 0.902 
(0.6 – 31.7) (0.1 – 11.1) 
Triple antiretroviral therapy 122 71 58.2 4 0.172 1.3 0.81 
(0.5 – 28.7) (0.1 – 12.8) 
Other 16 6 37.5 2.4 0.415 0.6 0.644 
(0.3 – 20.2) (0.1 – 6.4) 
                                                 
21
 Indicates maternal viral load at the antenatal baseline visit.  When the 3 categories of viral load were collapsed into 2 groups, greater than 100 
000 copies/ml (n=25) and less than 100 000 copies/ml (n=201) , the association between maternal viral load and infant upper respiratory illness 
was no longer significant, P> 0.05 
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Table 6 (contd.) 
Characteristic N n % 
Unadjusted hazards 
ratio 







Primiparity 86 43 50.0 1.0 1.0 
Multiparity 161 83 51.6 0.9 0.458 1.2 0.497 
 
(0.6 – 1.3) (0.7 – 1.9) 
Mode of delivery 
Emergency C/S 74 43 58.1 1.0 1.0 
Elective C/S 89 45 50.6 0.9 0.691 1.3 0.217 
(0.6 – 1.4) (0.8 – 2.2) 
NVD 91 44 48.4 1.0 0.664 1.3 0.234 
 
(0.7 – 1.7) (0.8 – 2.1) 
Sex of infant 
Male 120 63 52.5 1.0 1.0 
Female 125 63 50.4 0.7 0.14 0.7 0.131 
(0.5 – 1.1) (0.5 – 1.1) 
Gestational age at delivery 
≥ 37 weeks 187 93 49.7 1.0 1.0 
< 37 weeks 22 16 72.7 1.5 0.118 2.7 0.002 
 
(0.9 – 2.6) (1.4 – 5.3) 
LTFU of infant 
Not LTFU 154 109 70.8 1.0 1.0 
LTFU 104 23 22.2 1.0 0.881 1.2 




Table 6 (contd.) 
Characteristic N n % 
Unadjusted hazard 
ratio 
(95% CI) p-value 
Adjusted hazard ratio 
(95% CI) p-value 
Infant birth weight, g 
< 2500 27 14 51.9 1.0 1.0 
≥ 2500 215 112 52.1 1.1 0.65 1.3 0.359 
 
(0.7 – 2.0) (0.7 – 2.5) 
Infant cotrimoxazole prophylaxis 
No 80 19 23.8 1.0 1.0 
Yes 178 113 64.5 1.7 0.043 2.2 
(1.0 - 2.7) 
 
(1.2 – 3.9) 
 0.011 
Number of subjects = 258 
Number of failures = 132 
Time at risk = 5349 child-weeks 
Number of observations = 258 
Log likelihood = - 582.30718 
Logistic regression chi square (30df) = 58.22 
Prob > chi square = 0.0015 
 
The original models considered all the biological and socio-economic variables listed in table 1.   
Log likelihood criteria p > 0.1 for the following exposure variables; hence eliminated from the final model: 
Maternal race; maternal employment status; maternal death; smoking; illicit drug use; gestational age of foetus at first antenatal visit; 
preterm labour; obstetric sepsis; feeding method at birth reported by mother; HIV-infection status of the infant; sex of infant; and number of 
visits to McCord Hospital 
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4.3.3.4 Hospital admissions 
Overall, 21 of 265 (7.9%) children had one hospital admission (Table 7) at an incidence 
rate of 0.3 admissions per 100 child-weeks (95% CI: 0.2 to 0.4 admissions per 100 child- 
weeks).   
Table 7: Timing of hospitalisation of infants born to HIV-infected women who 
attended the Prevention of Mother-to-Child Transmission programme at McCord 













weeks at risk 
Early neonatal (0-6 days) 4 (1.5) 1.7  0.6 - 4.5 
Late neonatal (7-28 days) 0 (0) 0 - 
Post neonatal (> 28 days 17(6.4) 0.2 0.1 - 0.3 
 21 (7.9) 0.3   0.2 - 0.4 
N = 265 infants 
The reason for hospital admission was unknown in 15 (71.4%) infants (Table 8).  Two 
children were admitted with lower respiratory tract infection (9.5%).  One child was 
admitted with acute gastroenteritis (4.8%), and three children (14.3%) were admitted with 
diagnoses classified as “other” (one with burn injuries, one with cellulitis and one child for 




Table 8: Cause of hospital admissions in infants born to HIV-infected women who 
attended the Prevention of Mother-to-Child Transmission programme at McCord 
Hospital, from 1 May 2008 to 31 May 2009 
Cause of hospitalisation N       
* 
         % 
Unknown 15  71.4  
Lower respiratory tract 2  9.5 
Acute gastroenteritis 1 4.8 
*Other 3  14.3   
 21  100   
 N = 265 *Three admitted infants were classified as “other” – one with cellulitis, one with burns, and 
one infant was premature  
4.3.3.5 HIV transmission 
Overall, the HIV transmission risk was 2.7% (n=6; 95% CI: 1.0% to 5.8%) in the 220 
(83.0%) infants who had a DNA polymerase chain reaction assay taken at 6 weeks.  The 
HIV status was therefore unknown in 45 infants (17.0%) at 6 weeks of age.  None of the 
13 infants who were followed-up until 18 months of age were diagnosed as HIV-infected.   
4.3.3.6 Mortality of infants from birth to five months 
Among 231 infants in the cohort, the perinatal mortality rate was 13.0 per 1000 live births 
(95% CI: 2.7 to 37.4 per 1000 live births) (Table 9).  After exclusion of stillborns (n=3) and 
infants lost to follow-up by 5 months (n=84), the neonatal mortality rate was 3.8 per 1000 
live births (n=1; 95% CI: 0.0 to 21.0 per 1000 live births) and 27.6 per 1000 live births 
(95% CI: 9.0 to 63.3 per 1000 live births) cumulatively by five months (five deaths).  There 
were no deaths from birth to seven days (Table 9). The HIV-infection status was unknown 
for five of the infants that died.  One infant that died was presumed HIV-uninfected.   
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Table 9: Mortality rate of infants born to HIV-infected women in a Prevention of 
Mother-to-Child Transmission programme at McCord Hospital, from 1 May 2008 to 
31 May 2009 
Timing of mortality       
n 
Mortality rate  




Stillborn* 3  13.0*  2.7 – 37.4 
Birth to 28 days** 1 4.4* 1.0 – 23.9 
Birth to five months** 5  27.6**  9.0 – 63.3 




Of the 265 live births, five infants died.  Of the remaining 260 infants, 105 infants (40.4%; 
95% CI: 34.4% to 46.6%) were lost to follow-up compared to the 155 infants (59.6%; 95% 
CI: 53.4% to 65.6%) still in care at McCord Hospital (Table 10).   
Table 10: Proportion lost to follow of infants born to HIV-infected women who 
attended a Prevention of Mother-to-Child Transmission programme at McCord 
Hospital, from 1 May 2008 to 31 May 2009 
Variable        n % 95% 







34.4 - 46.6 
53.4 - 65.6 
N = 260 infants 
Thirty-four infants were lost to follow-up in the first week of life (Table 11).  The incidence 
rate of loss to follow-up of infants during this period was 14.5 per 100 child-weeks (95% 
CI: 10.3 to 20.3 per 100 child-weeks) (Table 11).The incidence rate of loss to follow-up 
declined steadily after the first week of life.  From one week to ten weeks, the incidence 
rate of attrition was 1.8 per 100 child-weeks (95% CI: 1.3 to 2.5 per 100 child-weeks).  
Sixteen infants were lost to follow-up between 11 and 19 weeks (incidence rate 1.0; 95% 
CI: 0.6 to 1.6 per 100 child-weeks).  The incidence rate of loss to follow-up of infants 
between the time periods 20 to 28 weeks and more than 28 weeks halved from 0.6 per 
100 child-weeks (95% CI: 0.3 to 1.2 per 100 child-weeks) to 0.3 per 100 child-weeks (95% 
CI: 1.0 to 1.4 per 100 child-weeks) respectively.   
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Table 11: Timing of loss to follow-up of infants born to HIV-infected women in a 
Prevention of Mother-to-Child Transmission programme at McCord Hospital, from 1 
May 2008 to 31 May 2009 
Timing of loss to follow-up, 
weeks 
n Incidence rate  
(per 100 child-weeks) 
95%  
Confidence Interval 
0 <1  34 14.5 10.3 - 20.3 
1- 10  34 1.8 1.3- 2.5 
11-19  16 1.0 0.6 - 1.6 
20-28  10 0.6 0.3 - 1.2 
> 28  11 0.3 1.0 - 1.4 
N = 260 infants 
4.3.4.1 Maternal socio-demographic, clinical and immunologic factors associated 
with loss to follow-up of infants 
Cox regression analysis was conducted to determine the predictors of loss to follow-up of 
infants at McCord Hospital22 (Table 12).  After exclusion of second and third infants of 
multiple births and infant deaths, 104 infants were lost to follow and 149 infants remained 
in care at McCord Hospital.   
In terms of demographic and socio-economic characteristics, in the multivariable analyses, 
maternal age less than 30 years (n=68; AHR 1.3; 95% CI: 0.8 to 2.1) and being single 
(n=89; AHR 1.2; 95% CI: 0.6 to 2.4) increased the risk of being lost to follow-up but the 
association was not statistically significant.  Compared to infants born to mothers whose 
race was unknown, infants whose mothers were classified as Black South Africans were 
40% less likely to be lost to follow-up (n=37; AHR 0.6; 95% CI: 0.4 to 1.0; p= 0.035).  
Unemployment was not a risk factor for attrition of infants at McCord Hospital (n=34; AHR 
0.9; 95% CI: 0.6 to 1.4; p = 0.636).   
Clinically, maternal disease staging was absent from 89.5% of patients’ charts and could 
not be used as a predictor of loss to follow-up of infants.  Maternal CD4 + count was used 
as a marker of immunological status.  In both the crude and adjusted model, maternal 
CD4+  count equal to or greater than 500 cells/mm3 (n=18; AHR 1.9; 95% CI: 1.0 to 3.7; p 
= 0.041) was associated with loss to follow-up infants but the association did not remain 
                                                 
22
 The Cox proportional hazards regression analysis was conducted by myself after consultation 
with Ms Tonya Esterhuizen, a biostatistician, who taught me how to conduct the analysis. 
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statistically significant after adjustment for confounders (AHR 1.6; 95% CI: 0.9 to 3.1; p = 
0.142).   
Biological variables were included in the multivariable analysis of loss to follow-up.  Infants 
born to mothers who had their first antenatal visit at or after 28 weeks were 2.3 times more 
likely to be lost to follow-up, relative to infants whose mothers booked in their first 
trimester. The association was statistically significant (n=31; 95% CI: 1.0 to 5.1; p = 0.044).  
In addition, mode of delivery was independently significantly associated with loss to follow-
up.  Infants whose mothers had a normal vaginal delivery (n=41; AHR 2.5; 95% CI: 1.4 to 
4.5; p = 0.002) or an elective caesarean section (n= 39; AHR 1.9; 95% CI: 1.1 to 3.5; p = 
0.028) were more likely to be lost to follow-up.  Maternal parity (primiparous) was a risk 
factor for loss to follow-up of infants but the association did not reach statistical 
significance (n=41; AHR 1.4; 95% CI: 0.8 to 2.2; p = 0.212).
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Table 12: Cox regression analysis of maternal socio-demographic, clinical and immunologic factors associated with loss to 
follow-up of infants born women in a PMTCT programme at McCord Hospital, from 1 May 2008 to 31 May 2009 
 












≥ 30 years 107 36 33.6 1.0 1.0 
< 30 years 144 68 47.2 1.5 0.061 1.3 0.28 
(1.0 – 2.2) (0.8 – 2.1) 
Marital status   
Married 37 12 32.4 1.0 1.0 
Single 210 89 42.4 1.4 0.254 1.2 0.526 
(0.8 – 2.6) (0.6 – 2.4) 
Race 
Unknown 130 65 50.0 1.0 1.0 
Black (South African) 117 37 31.6 0.6 0.007 0.6 0.035 
(0.4 – 0.9) (0.4 – 1.0) 
Employed 
Yes 162 65 40.1 1.0 1.0 
No 84 34 40.5 1.0 0.948 0.9 0.636 
(0.7 – 1.5) (0.6 – 1.4) 
Gestational age at booking 
0 – 12 weeks 29 8 27.6 1.0 
 
 1.0 
13 - 27 weeks 151 58 38.4 1.4 
 
0.343 1.6 0.246 
(0.7 – 3.0) (0.7 – 3.4) 










(0.9 – 4.4) 0.079 
2.3 
(1.0 – 5.1) 0.044 
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Table 12 (contd.) 
       
Characteristics N n % 
Unadjusted  









CD4+ count (cells/mm3) 
< 200 66 20 30.3 1.0 1.0 
200 - 499 144 59 41 1.5 0.132 1.5 0.118 
(0.9 – 2.5) (0.9 – 2.6) 
≥ 500 35 18 51.4 1.9 0.041 1.6 0.142 
(1.0 – 3.7) (0.9 – 3.1) 
Parity 
Multiparity 158 60 38 1.0 1.0 
Primiparity 84 41 48.8 1.4 0.121 1.4 0.212 
(0.9 – 2.0) (0.8 – 2.2) 
Mode of delivery 
Emergency C/S 73 20 27.4 1.0 1.0 
Elective C/S 89 39 43.8 1.7 0.047 1.9 0.028 
(1.0 – 3.0) (1.1 – 3.5) 
NVD 87 41 47.1 2.0 0.012 2.5 0.002 
        (1.2 – 3.4)   (1.4 – 4.5)   
 
Number of subjects = 253 
Number of observations = 253 
Number of failures = 104 
Time at risk = = 61 163 
Logistic regression chi square (19 df) = 54.78 
Log likelihood = -517. 76801 
Prob > chi square = 0.0000 
The original models considered all the biological and socio-economic variables listed in table 1.   
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Log likelihood criteria p >0.1 for the following exposure variables; hence eliminated from the final model 
Maternal death; smoking; illicit drug use; maternal baseline viral load (taken at the first antenatal visit); maternal illness during 
pregnancy, maternal antiretroviral regimen during pregnancy; preterm labour; obstetric sepsis; maternal mortality; feeding method 




4.3.4.2 Reasons for attrition of infants at McCord Hospital 
The reasons for attrition of infants at McCord Hospital are shown in Table 13.  The reason 
for loss to follow-up of infants was missing in the majority of cases (n=83; 79.8%).  
Maternal employment (n=1; 1.0%) infant residing with someone else (n=6, 5.8%), and 
attending a clinic closer to home (n=6, 5.8%) were reported by mothers as reasons for 
attrition.  “Other” reasons were reported for nine infants lost to follow-up at McCord 
Hospital.  These reasons included financial problems (n=4), transport issues (n=3), 
adoption (n=1), and maternal death (n=1) 
Table 13: Reasons reported by mothers for loss to follow-up of infants born in a 
Prevention of Mother-to-Child Transmission programme at McCord Hospital, from 1 
May 2008 to 31 May 2009 
Reasons for loss to follow-up of infants n % 
Mother working 1 1.0 
Infant living with someone else 6 5.8 
Attending a clinic closer to home 6 5.8 
Other reasons* 9 8.7 
Reason for loss to follow-up missing 83 79.8 
N = 105 infants lost to follow-up (includes infants of multiple births) 
*Four mothers reported financial issues, three mothers had problems with transport, one infant 
was adopted, and one mother died 
4.4 SUMMARY 
The majority of HIV-infected mothers attending the Prevention of Mother-to-Child 
Transmission programme at McCord Hospital were single, employed, South African Black 
women and were less than 30 years old.  Infants in the cohort were predominantly 
formula-fed at birth and were HIV-uninfected.  Infections of the upper respiratory tract 
were most frequent in infants.  In the multivariable analysis, there was a significant 
association between gestational age of delivery, high maternal viral load and the use of 
infant cotrimoxazole prophylaxis and first upper respiratory illness in infants.  An estimated 
forty per cent of infants were lost to follow-up after delivery.  Maternal race, gestational 
age of the foetus at the first antenatal visit and mode of delivery were significantly 




5 CHAPTER V: DISCUSSION 
5.1 INTRODUCTION  
In chapter five, the clinical and loss to follow-up outcomes of infants born to HIV-infected 
women who received antiretroviral prophylaxis or therapy at McCord Hospital are 
discussed.  The significance of the risk factors associated with upper respiratory illness 
and loss to follow-up of infants are explored in view of the biological plausibility of these 
associations and the findings of other studies are analysed.  The findings of this study are 
also considered in light of the possible biases and limitations of the study design, the data 
collection process and results obtained in the study.  The generalisability of the study to 
the antenatal HIV-infected population South Africa is also discussed.   
5.2 FINDINGS  
The format of the discussion is similar to the results. 
5.2.1 Socio-demographic characteristics of HIV-infected women and their infants 
attending the Prevention of Mother-to-Child Transmission programme at 
McCord Hospital  
The socio-demographic characteristics of this study population differ somewhat from other 
observational studies documenting the follow-up characteristics of infants born to HIV-
infected women who received antiretroviral prophylaxis or therapy antenatally 27, 47.  The 
majority of the women at McCord Hospital were employed (n=165, 65.7%) compared to 
one prospective study in Latin America and Caribbean countries where only 23.6% 
(N=462) of women in the study were employed.  The median maternal age of HIV-infected 
women in this study was 28.0 years, which is older than HIV-infected women who 
received antiretroviral prophylaxis or therapy in a cohort study in three Prevention of 
Mother-to-Child Transmission pilot sites23 in South Africa 39 and a cohort study in Malawi24 
(mean maternal age 24.1 years) 47.  The median maternal age of women in this study was 
comparable to the median maternal age of women in a cohort study conducted in eight 
European countries 69.  The antiretroviral regimen prescribed to women at McCord 
Hospital differed from the national guidelines and almost 48% of women were on triple 
                                               
23
 Mean maternal age 25.8 years in Paarl, 26.1 years in Umlazi and 24.1 years in Rietvlei 
24




therapy.  Whilst this may seem like a substantial proportion of women in the prevention of 
mother-to-child transmission programme on lifelong antiretroviral therapy, 84.6% (n=104) 
was indicated due to low CD4+ count either in the current or prior pregnancy.  
The birth weight of infants in this study was slightly greater than the birth weights of 
infants in the cohort study at three Prevention of Mother-to-Child Transmission sites in 
South Africa 39 and comparable to a non-randomised cohort study in antenatal clinics 
KwaZulu-Natal 54. The gestational age at birth of infants in this study was comparable to 
the three South African sites 39.   
One of the objectives of the Well Mother and Baby Clinic at McCord Hospital was to 
improve the post-natal care of infants receiving peri-natal antiretroviral therapy.  The 
proportion of infants receiving BCG and polio vaccines at birth should have been 100% 
and the low coverage of 83% was worse than coverage of infants born to HIV-infected 
women in a rural district in KwaZulu-Natal 72.  The proportion of infants having received 
their third dose of oral polio vaccine was 71.3%, which is still below the 80% target set by 
the World Health Organisation to achieve polio eradication 70.  The coverage of measles 
vaccine was far less than the 90% benchmark recommended by South Africa in 2003 71.  
Overall, the vaccination coverage achieved by McCord Hospital was worse than the 
coverage of infants born to HIV-infected women in a rural district in northern KwaZulu-
Natal 72.  The implementation of the rotavirus and pneumococcal vaccine25 at McCord 
Hospital was not evaluated in this study.  The reasons for the low coverage of BCG and 
polio and birth were unclear and of concern.  Factors affecting childhood vaccination 
status include maternal age 73, maternal education 74-77, maternal HIV status , distance to 
health care facilities 78-81, and household wealth 82, 83.  Studies have shown that children 
born into wealthier households have a higher probability of having their vaccination status 
checked and receiving missed doses of vaccines than children in poorer households.  
Given that the socio-economic profile of the women attending McCord Hospital was 
presumed to be better than that of the general population, the low vaccination coverage is 
unlikely to be related to socio-economic factors and may reflect the quality of care 
provided at the infant follow-up clinic at McCord Hospital.   
                                               
25
 Rotavirus and pneumococcal vaccines were implemented at McCord Hospital in November 2008 
and this data was inconsistently collected.   
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5.2.2 Types of infections 
In this cohort of predominantly non-breastfed, HIV-exposed, uninfected infants at McCord 
Hospital, approximately two-thirds of the infants experienced infectious disease morbidity 
from birth to 18 months.  This study found an incidence rate of upper respiratory infection 
greater than that of cohort studies in both developing (0.89 cases per 100 child-weeks in 
Latin America) 27, 84 and developed settings (2.0 cases per 100 child-weeks in United 
States 85.  
Conversely, the observed rate of lower respiratory tract infections in this study was less 
than half that observed in a Latin American cohort study (0.9 cases per 100 child-weeks) 
27, a randomised trial of formula-fed uninfected infants in Kenya (7.1 per 100 person-
weeks) 86, and a multicentre cohort study in the United States (2.8 cases per 100 child-
weeks) 85.  Only two infants in the study were admitted with lower respiratory tract 
infection (9.5%) compared to 40.7% of infants who were admitted with lower respiratory 
tract infection in a Latin American study 27.  The proportion of infants diagnosed with 
pulmonary tuberculosis by three months of age in this study (n=2; 0.8%) was lower than 
that of infants with culture confirmed cases of pulmonary tuberculosis at the same age in a 
prospective cohort study (33/596; 5.5%) in two hospitals in Cape Town, South in 2005 87.    
The study findings of 169 skin and mucous membrane infections (30.9%) was higher than 
that detected in a Brazilian cohort study in urban slums (5.9%) 84.  However, the incidence 
rate of skin infections was comparable to that observed in the Latin-American study (1.9 
cases per 100 child-weeks) 27.  The diagnosis of upper respiratory tract infection was 
dependent on both parental recall and the clinical diagnosis of illness during a scheduled 
or unscheduled visit.  Although, there is a possibility of overestimation of upper respiratory 
infections, this was less likely for skin and mucous membrane infections as the clinical 
diagnosis was less subjective.   
The incidence rate of gastrointestinal infections was two-fold higher than that observed in 
the Latin-American study (0.3 per 100 child-weeks).  However, the proportion of 
gastrointestinal infections was much lower than that found in infants (35.1%) in the 
Brazilian cohort 84, in two hospitals (30.6%) (King Edward VIII and McCord Hospital) in 
South Africa from 1995 to 1998, and in formula feeding uninfected infants in Kenya (21.4 
per 100 person-weeks) 86, 88.  It is difficult to comment on the effect of infant feeding on the 
incidence of infections as the feeding methods reported by the mother were not validated.  
Whilst the incidence of skin and upper respiratory tract infections were higher or 
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comparable to other developing countries, the lower incidence of gastrointestinal and 
lower respiratory tract infections may be reflective of the better socio-economic profile of 
the HIV-infected women attending McCord Hospital.  The implementation of rotavirus and 
pneumococcal vaccine may have reduced the incidence of lower respiratory tract and 
gastrointestinal infections but this intervention was not assessed.   
The reason for upper and lower respiratory and skin infections occurring from 61 to 120 
days of age compared to gastrointestinal infections which occurred after 240 days in this 
study was unclear.  HIV-infected women who did not breastfeed may have exposed their 
infants to dietary pathogens and hence increased the risk of morbidity from non-HIV 
related infectious diseases 54, 67, 89, 90.  The higher incidence of gastrointestinal infections 
after 240 days may be related to weaning and introduction of solid foods 55, 91, 92.  
However, further research at McCord Hospital on the association between feeding 
practice and infant morbidity is required to answer these questions. 
5.2.3 Factors associated with upper respiratory tract infection 
The lack of association between maternal demographic risk factors and infant upper 
respiratory events in the multivariable model was surprising but may be indicative of the 
better socio-economic profile of the mother.  Factors that were associated with neonatal 
and post neonatal infections but not measured in this study were maternal use of 
intrapartum antibiotics, maternal CD4+ count at hospital discharge, tobacco smoking 
during pregnancy, number of persons living in the household, indoor air pollution and 
infant anaemia 27, 93.   
The factors associated with upper respiratory illness in HIV-exposed infants in this study 
included maternal viral load antenatally, the infant’s gestational age at delivery and the 
use of infant cotrimoxazole prophylaxis.   
This study demonstrated that maternal viral load above 10 000 copies/ml at the baseline 
antenatal visit was significantly associated with upper respiratory illness in the infant.  In 
HIV-infected patients, plasma viral load is a predictor of the rate of decline in CD4 + count 
and progression to AIDS and death 94. In a multicentre cohort study of 1604 patients, 
55.2% of patients with viral loads between 10 000 copies/ml and 30 000 copies/ml 
progressed to AIDS within six years of follow-up 94.  If the maternal viral load at baseline is 
taken as an indicator of maternal progression to AIDS, then it might be possible to explain 
the association between the higher maternal viral load and infant upper respiratory illness.  
Several studies have shown the association between stage of maternal disease and infant 
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morbidity and mortality 27, 40. The exact link between stage of maternal disease and infant 
morbidity is still uncertain and a few theories have been postulated.  The first is the 
reduced level of maternal antibody titres to common pathogens with inadequate trans-
placental transfer of maternal antibodies 95.  Secondly, in-utero exposure and failure of 
maternal immune system secondary to HIV may result in inadequate immune functioning 
in the infant.  Subsequently the infant is unable to resist common infections.  These 
changes may persist over time 96, 97.  Other abnormalities in cytokine production have 
been shown in HIV-exposed, uninfected infants but the association between specific 
abnormalities and infant morbidity or mortality is not established 98, 99.  Lastly, deteriorating 
health in the mother due to HIV-infection could lead to increased morbidity in the infant 47. 
Preterm delivery at less than 37 weeks of gestation was shown to be a risk factor for the 
infant experiencing an upper respiratory event.  This  association may be explained by 
predisposition of preterm infants to infections due to immaturity of the immune system and 
longer periods of hospitalisations, which may increase the risk acquiring nosocomial 
infections 100.   Preterm infants also have inadequate functioning of the alternate and 
complement pathways required for complement- mediated opsonisation, that is, the 
alteration of antigens for phagocytosis and destruction by immune cells 100. Moreover, the 
process of phagocytic migration to the site of infection is dampened in preterm infants 
further predisposing them to infections from common pathogens 100.  Immune 
mechanisms against viral pathogens in the preterm infant may also be lacking due to the 
absence of antibody-dependent, cell-mediated immunity by natural killer lymphocytes 100.  
The sample of infants who were born preterm was small (n=22) and this may have 
overestimated the effect found.  In addition, the association between upper respiratory 
illness and preterm infants may be subject to recall bias with mothers of preterm infants 
more likely to recall an upper respiratory episode in their infants relative to women whose 
infants were born at term.   
The observation that the prophylactic use of cotrimoxazole in infants is a predictor for 
upper respiratory events is contradictory to what might be expected.  Previous studies 
have shown cotrimoxazole prophylaxis has improved survival and changed the pattern of 
respiratory infections of HIV-infected children 101-103.  In addition to preventing infection 
with Pneumocytis jiroveci, cotrimoxazole prophylaxis may also prevent illness secondary 
to other bacterial infections and malaria 104.  These benefits also extend to HIV-uninfected 
infants 104.  A previous cohort study in South Africa demonstrated an increase in 
diarrhoeal disease in infants to whom cotrimoxazole prophylaxis was administered 88.  
However, the study was subject to loss to follow-up bias.  The findings of this study of 
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cotrimoxazole prophylaxis as a risk factor for upper respiratory illness in infants may be 
due to random error. 
5.2.4 HIV transmission 
Similar to the previous cohort study at McCord Hospital 21, the proportion of infants who 
were presumed HIV-infected at six weeks was small (2.7%; 95% CI: 1.0% to 5.8%).  
Findings from a one-year HIV surveillance study of primary health care clinics offering 
prevention of mother-to-child transmission services showed that the mother-to-child 
transmission risk of HIV in the general population was much higher than at McCord 
Hospital 105.  According to the data in this study the vertical transmission was 20.2% 
(n=188; 95% CI: 17.7% to 24.2%) among all HIV-exposed infants (n=931) at 4 to 8 weeks 
of age and 15.0% (95% CI: 11.9% to 18.6%) in infants whose mothers reported the use of 
sd-nevirapine 105.   
However, given the large proportion of infants who were lost to follow-up in the first ten 
weeks following delivery in this study, and were not tested for HIV-infection, it is likely that 
there was an underestimation of the HIV transmission risk at McCord Hospital.  If the 
infants who died (n=5) in the study were assumed to be HIV-infected, and proportionally 
the same number of infants whose HIV status was unknown (1/45; 2.7%) were assumed 
to be infected as those whose HIV status was known at 6 weeks, then the HIV 
transmission risk in this study increased to 4.5%26 at 6 weeks.   
A small proportion of infants (4.9%) reached the 18-month follow-up period at McCord 
Hospital and were confirmed HIV-uninfected.  Infants who were presumed27 HIV-
uninfected at six and 14 weeks require further testing at 18 months in order to confirm the 
low HIV transmission risk at McCord Hospital.   
5.2.5 Mortality of infants 
The five-month mortality of infants in this study (27.6 per 1000 live births) was higher than 
the six-month mortality of infants in a cohort study in Latin American and Caribbean 
countries (n=462) (12.3 per 1000 live births) 27..The neonatal mortality rate shown in this 
study was four times less than the 2004 South African estimate (17 per 1000 live births) 9 
                                               
26
 6 infants known HIV infected + 5 infants died assumed infected + 1 infant with unknown status 
assumed infected out of 265 infants in the cohort 
27
 An infant was presumed HIV-1 uninfected if they had ≥ two negative DNA polymerase chain 
reaction assays at McCord Hospital with the first test performed at six weeks of age and the 
second test performed at 14 weeks of age. 
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which may be related to the socio-demographic characteristics of the study population.  
The cause of the five infant deaths was unknown.  It was not possible to do statistical 
analyses to determine the predictors of mortality as the number of deaths in the infant 
cohort was small.  As with HIV transmission risk, it is possible that mortality in this infant 
cohort was underestimated, due to the poor retention of infants in the study.   
5.2.6 Factors associated with loss to follow-up of infants 
The proportion of attrition of infants in this study was higher than a prospective study in 
Malawi (n=653; 30.3%) 50 and a cohort study in Johannesburg (22.3%) 48, but 10% less 
than a programmatic study in rural Uganda (n=303; 53%) 51.  The incidence rate of loss to 
follow-up of infants in the study was highest in the week following delivery and diminished 
as the infants grew older.  The reason for loss to follow-up of infants was missing in the 
majority of cases.  The antiretroviral regimens provided by McCord Hospital differ from the 
public sector.  Women attending the Prevention of Mother-to-Child Transmission 
programme at McCord Hospital may do so to ensure better care for their infants.  After 
delivery, women may seek care at their regular clinics or hospitals.  Financial and 
transport issues may determine the retention of infants at the hospital. 
In the multivariable Cox proportional hazards model, although maternal age less than 30 
years and being single was a risk factor for loss to follow-up of infants in this study, the 
association did not remain significant after adjustment.  Unemployment was not a 
significant predictor of loss to follow-up of infants, unlike the cohort study in Malawi 50, but 
the socio-demographic characteristics of these study populations are not comparable.  
The lack of association between recorded maternal demographic characteristics with 
attrition of infants is probably indicative of the higher socio-economic profile of this group.  
However, this finding could not be confirmed, as maternal socio-economic measures, 
such as income and type of housing, were not routinely collected by McCord Hospital.  
Mothers who were categorised as Black South Africans in this study were less likely to be 
lost to follow-up relative to women whose race was unknown.  When race of unknown 
women in the cohort was assumed to be Black South Africans in the multivariable model 
of this study, the association between maternal race and loss to follow-up did not remain 
significant (AHR 0.8; 95% CI: 0.2 – 3.8; p=0.839).   
This study demonstrated that relative to infants of HIV-infected women with CD4 + counts 
equal to or less than 200 cells/mm3, infants born to mothers with CD4+ counts above 200 
cells/mm3  were more likely to be lost to follow-up, but the finding was not statistically 
significant.  Maternal well-being may be a risk factor for poor retention at McCord Hospital 
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as mothers do not perceive themselves or their infants to be at risk for disease and are 
hence less likely to seek health care. A similar correlation between infant wellbeing and 
loss to follow-up was shown in a study in rural Uganda, where infant illness was a 
protective against loss to follow-up in the Prevention of Mother-to-Child Transmission 
programme 51.   
The Ugandan study showed that incomplete or absent antiretroviral prophylaxis taken by 
the mother or the infant was a risk factor for loss to follow-up 51.  However, when maternal 
and infant antiretroviral regimen and baseline viral load28 was initially included in the 
multivariable model in this study, no correlation was found with loss to follow-up.  These 
variables were subsequently removed from the model (p > 0.1) 
Infants of HIV-infected women who presented at or after 28 weeks of gestation for their 
first antenatal visit were more likely to be lost to follow-up relative to infants whose 
mothers presented early for care.  This finding suggests that late presentation for 
antenatal care was related to poor maternal health seeking behaviours and therefore 
increases the likelihood that the infant is lost to follow-up.  An alternate explanation may 
be that these women have differing demographic or socio-economic profiles compared to 
women who present early in their pregnancy for antenatal care that have not been 
measured (for instance education level, income status, or distance from the hospital). 
In the multivariable model, having an elective caesarean section or normal vaginal 
delivery relative to an emergency caesarean section was shown to be a predictor of loss 
to follow-up of infants in this study.  A possible explanation for this finding is that women 
who have emergency deliveries were more concerned for the wellbeing of their infants, 
following the indication for the emergency surgery, and hence more likely to seek care for 
their infants. 
5.3 VALIDITY 
This section discusses the internal validity of the study, which refers to whether the 
outcomes of this study are a function of the variables measured.  The generalisability of 
the study findings to the population was also considered under external validity.   
                                               
28
 Baseline maternal viral load and maternal antiretroviral regimen taken during pregnancy was 
initially included in the model of risk factors associated with loss to follow-up of infants but was not 
statistically significant (p> 0.1) and was eliminated from the model 
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5.3.1 Internal validity  
Two main data sources were used to extract maternal and infant exposure and outcome 
variables.  
Some exposure variables were missing from patient files.  Routine maternal demographic 
data on race were absent from patient charts for the early period of the study from May 
2008 to November 2009.  Thereafter, the counsellors at McCord Hospital began collecting 
routine demographic and psychosocial data from all mothers attending the Well Mother 
and Baby Clinic at McCord Hospital.  Data on World Health Organisation staging of HIV 
disease on enrolment of women in the Prevention of Mother-to-Child Transmission 
programme at McCord Hospital were not recorded in 90% of maternal records. 
Maternal anthropometric data were collected when mothers were at different gestational 
ages as it was recorded when they presented for their booking antenatal visit. The 
consequence is that the anthropometric data were probably not comparable.  In addition, 
baseline data on height (20.9%) and weight (15.9%) were absent from patient files and 
could not be used as an exposure variable.   
Maternal antenatal illnesses were diagnosed and recorded by clinical staff (general and 
specialist practitioners) in the maternal records and could not be verified.  These maternal 
diagnoses ranged from minor to major illnesses.  In some instances of serious illness 
events, laboratory or radiological evidence were available to confirm the diagnosis.  
Maternal illness events during the pregnancy were extracted from maternal records.  If the 
clinician in the presence of symptoms or signs of illness recorded no clinical diagnosis, the 
illness event was not captured for this study. 
With respect to infant illness events, presumptive diagnoses of infection were made by 
nurses, or family practitioners at McCord Hospital, and recorded in the infants’ records.  
The researcher could not verify these diagnoses.  Data were collected on infant feeding at 
birth and follow-up visits.  However, this data were based on maternal or caregiver report 
and was not validated.   
Infant anthropometric measurements were taken at birth and follow-up visits by the clinical 
staff at McCord Hospital.  These measurements were not standardized. 
Assignment of infant HIV-infection status was based on two or more HIV-1 DNA 
polymerase chain reaction assays at six and 14 weeks and two HIV Elisa antibody tests at 
18 months.  Data on loss to follow-up of infants were based on the date of the last visit 
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and date of the next expected visit to McCord Hospital.  The researcher assigned loss to 
follow-up status of infants.  Staff at McCord Hospital was aware of patients who had 
missed the scheduled visits.  These patients were contacted telephonically to verify their 
intent to return to the hospital or their reason for missing the scheduled visit.   
Infant mortality was based on caregiver report and could not be verified.  The date and 
cause of death was also not confirmed.   
5.3.2 External validity 
McCord Hospital is a semi-private institution.  HIV-infected women at McCord Hospital are 
subsidised by donor funding or pay user fees to attend the Prevention of Mother-to-Child 
Transmission programme.  Although, no user fees were charged to infants born to these 
women to attend the Well Mother and Baby Clinic and receive routine care, the results of 
this study are not generalisable to the HIV-exposed infant population in South Africa.  The 
results of this study can be generalised to infants born to HIV-infected women who attend 
Prevention of Mother-to-Child Transmission services in urban, semi-private settings. 
5.4 BIAS AND LIMITATIONS 
The bias and limitations of this study are discussed with regards to its design, data 
collection and the findings of the study. 
The major limitation to this study was the retrospective nature of the cohort design.  
Although data were prospectively collected, it was not possible to assess the potential 
effect of other risk factors that may have contributed to loss to follow-up or infant illness 
from routinely collected clinical records.  Risk factors such as maternal education, income 
level, number of people living in the household, paternal factors, number of siblings and 
infant anaemia were variables that were not routinely collected so could not be assessed. 
Clinic staff routinely collected data on the reasons infants were lost to follow-up by 
telephoning the caregivers.  However, in the majority of instances the reason for lost to 
follow-up was missing and was a limitation of the study.  In particular, the contribution of 
infant feeding practices to the clinical outcomes of the infants could not be determined, as 
this exposure variable was not validated by administration of a feeding questionnaire to 
the mothers or observation of feeding practice practiced by the mothers.  Data on infant 
feeding practice were instead based on maternal report. 
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Another limitation of this study was the selection of the study population.  According to the 
selection criteria29, infants not delivered at McCord Hospital or were not brought back to 
the hospital for follow-up care were excluded from the study.  This constitutes a selection 
bias.  Furthermore, the study did not include a comparison group of infants born to HIV-
uninfected women from McCord Hospital, which would have made it possible to determine 
the background risk of HIV-exposed uninfected infants in terms of infectious disease 
morbidity and loss to follow-up. 
McCord Hospital is a semi-private institution.  Women were either charged a user-fee or 
subsidised by donor funding to attend the Prevention of Mother-to-Child Transmission 
programme.  The socio-economic profiles of women who paid for care may be different 
from women whose user fees were subsidised and represents a selection bias, which may 
have biased the effect observed in terms of loss to follow-up, morbidity and mortality 
towards the null  
In terms of the clinical outcomes of morbidity, mortality and HIV transmission risk, the high 
proportion of infants lost to follow-up would also result in a selection bias, and 
underestimate the effect observed.   
Information bias in the study may be attributed to the following: 
i. The skill levels of nurses and practitioners attending to HIV-infected mothers and 
infants differed in the Prevention of Mother-to-Child Transmission programme.  
This was likely to have resulted in a non-differential misclassification of clinical 
diagnoses of mothers and infants. 
                                               
29 Inclusion criteria: HIV-infected women who received antiretroviral prophylaxis or therapy in the 
McCord Prevention of Mother-to-Child Transmission Programme and either: 
1) Delivered their infants at McCord Hospital between 1 May 2008 and 31 May 2009; and/or  
2) Presented their infants for care to McCord Hospital, following delivery elsewhere, between 1 
May 2008 and 31 May 2009.  
Exclusion criteria:  HIV-infected pregnant women who received antiretroviral prophylaxis or therapy 





ii. Illness events may have been overestimated due to recall bias by the caregiver 
resulting in bias away from the null. 
iii. Estimation of illness in infants attending the clinic represented a cohort of infants 
who were well and subject to survival bias. 
iv. The loss to follow-up status of the infants was assigned by the researcher and may 
have resulted in an overestimation of the effect seen due to ascertainment bias.   
v. The researcher, a trained research assistant and a medical student conducted the 
data collection.  Data collection by the researcher may have resulted in an 
overestimation of the study outcomes away from the null.   
vi. Study data were entered only once into the study database by a single data 
capturer. 
 
A further limitation of the findings of this study was that growth of infants still needs to be 
determined as a further objective and was not assessed in this study due to insufficient 
time available to the researcher.  In terms of incidence of infectious diseases, infants who 
were HIV-exposed infected and uninfected infants were combined into one group due to 
the small sample size of HIV-infected infants.  When infants who were HIV-infected were 
excluded from the Cox proportional hazards model of risk factors associated with upper 
respiratory tract infection, there was no difference in the significance of the findings.   
The statistical analyses of this study were conducted by the researcher under supervision 
by a biostatistician at the University of KwaZulu-Natal. 
5.5 SUMMARY 
This study demonstrated clinical and loss to follow-up outcomes of predominantly HIV-
exposed, uninfected infants whose mothers received care at the McCord Hospital 
Prevention of Mother-to-Child Transmission programme.  The risks associated with upper 
respiratory illness and losses to follow-up of these infants were explored.  The study 
demonstrated that women with higher viral loads and preterm infants were more likely to 
experience an upper respiratory event.  Predictors for loss to follow-up of these infants 
were maternal factors such as the late presentation of women for first antenatal visit and 
having an elective caesarean section or normal vaginal delivery.  The periods of greatest 
risk in terms of infectious diseases and loss to follow-up was also described.  Knowledge 
of the timing and risk factors associated with infectious disease morbidity and loss to 
follow-up can facilitate the development of appropriate clinical interventions to improve the 




6 CHAPTER VI: RECOMMENDATIONS AND CONCLUSIONS 
6.1 INTRODUCTION 
This study observed high proportions of common infectious diseases and loss to follow-up 
of infants whose mothers attended the Prevention of Mother-to-Child Transmission 
programme at McCord Hospital.  The problem of poor follow-up presented a barrier to the 
effectiveness of the Prevention of Mother-to-Child Transmission programme at the 
hospital.  Increased proportions of dropout of infants were observed in HIV-infected 
women who presented late for their first antenatal visit and women who had normal 
vaginal deliveries or elective caesarean section.  Knowledge of risk factors associated 
with infectious disease morbidity and attrition of infants at McCord Hospital will facilitate 
the implementation of appropriate clinical interventions to reduce the frequency of 
common illnesses and loss to follow-up among these infants. 
6.2 CONCLUSIONS 
The Prevention of Mother-to-Child Transmission programme at McCord Hospital has been 
successful in reducing the HIV transmission risk of infants to less than 5% at 14 weeks of 
age, despite servicing a low to middle class population in a developing country.  The low 
vertical transmission was in line with that reported in resource-rich settings 22-24. 
Nonetheless, the five- month mortality of infants in this study was comparable to a cohort 
of infants in Latin America and Caribbean countries 27.  Although the burden of disease of 
infants in terms of pulmonary tuberculosis, lower respiratory and gastrointestinal infections 
were remarkably low, the incidence of upper respiratory and skin and mucous membrane 
illnesses was concerning, and exceeded that in other developing countries 27, 84. Preterm 
delivery and high maternal viral load predisposed infants to upper respiratory events and 
the greatest risk of illness occurred from two to four months.  Moreover, the low 
vaccination coverage at McCord Hospital, particularly the BCG and polio at birth, was 
concerning and falls short of national and international benchmarks.  While the low 
vaccination coverage may be a function of the attrition, the poor coverage of BCG and 
polio at birth indicate health system issues at facility level and further investigation is 
warranted.   
The proportion of infants lost to follow-up at McCord Hospital was greater than other 
Prevention of Mother-to-Child Transmission programmes in public settings in Africa 48, 50 
and was comparable to one other developing country 51.  The proportion of infants lost to 
follow-up was greatest in the week following delivery and represents a missed opportunity 
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to improve the health outcomes of HIV-exposed infants born to women in this Prevention 
of Mother-to-Child Transmission programme.   
6.3 RECOMMENDATIONS  
Recommendations are made to improve the loss to follow-up and morbidity outcomes of 
HIV-exposed infants born to women attending the Prevention of Mother-to-Child 
Transmission programme at McCord Hospital.  As McCord Hospital is a semi-private 
institution, these recommendations are implementable at facility level. 
The prevention of mother-to-child transmission and infant feeding guidelines in South 
Africa have undergone major transformation.  These changes are outlined below.  
At a policy level, the South African Department of Health implemented the new prevention 
of mother-to-child transmission guidelines on the 1 April 2010 18.  According to these 
guidelines, all pregnant women with CD4+ counts less than or equal to 350 cells/mm3 or 
World Health Organisation stage three or four are eligible for antiretroviral therapy and 
should be commenced on tenofovir, nevirapine and either lamivudine or emtracitabine 
depending on availability 18.  Pregnant women with CD4+ counts above 350 cells/mm3  or 
World Health Organisation stage one or two are eligible for antiretroviral prophylaxis with 
antenatal zidovudine commencing at 14 weeks, intrapartum single-dose nevirapine, three-
hourly zidovudine and a postpartum single-dose of tenofovir and emtracitabine 18.  HIV-
infected pregnant women with tuberculosis are regarded as having stage three disease 
and should be started on antiretroviral therapy 18. 
The infant guidelines on antiretroviral prophylaxis have also been revised 18.  The duration 
of nevirapine prophylaxis to the infant depends on the method of infant feeding and if the 
mother is on antiretroviral prophylaxis or therapy 18.  Criteria for six weeks administration 
of infant nevirapine prophylaxis are (i) infants who are exclusively formula fed, (ii) infants 
who are exclusively breastfed and the mother is on antiretroviral therapy, (iii) infants who 
are HIV-infected.  Infants who are exclusively breastfed and whose mothers are not on 
antiretroviral therapy should be provided with nevirapine until complete cessation of 
breastfeeding. According to these guidelines all breastfeeding should be stopped at one 
year of age 18. 
The World Health Organisation set new recommendations on infant feeding in the context 
of HIV in November 2009.  The WHO rapid advice guidelines recommended that all HIV-
uninfected infant be exclusively breastfed for six months, with the introduction of 
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complementary foods thereafter and continued breastfeeding until 12 months of age 59.  
The provision of breast milk should only be stopped once a nutritionally adequate, safe 
diet can be given to the infant.  The provision of commercial formula milk to the HIV-
uninfected infants should only be considered in a setting where formula feeding is 
affordable, feasible, acceptable, sustainable and safe 58, 59. 
In light of these changes, McCord Hospital should consider revising their Prevention of 
Mother-to-Child Transmission protocol in line with new Prevention of Mother-to-Child 
Transmission guidelines released by the South African National Department of Health. 
McCord Hospital should focus their efforts on improving the morbidity outcomes of 
preterm infants and infants born to women with baseline antenatal viral loads at or greater 
than 10 000 copies/ml.  These infants should be identified as high risk cases that require 
careful monitoring and active follow-up to ensure their continued well-being.  According to 
the new national prevention of mother-to-child transmission guidelines, all HIV-exposed 
infants should have weekly follow-up visits in the first month of life and monthly visits until 
one year of age 18.  However, these recommendations may be logistically impractical to 
implement. 
The low vaccination coverage at McCord Hospital warrants further investigation.  The 
issues surrounding poor coverage of BCG and polio at birth should be determined.  
Furthermore, health system issues, particularly in the period following delivery, should be 
resolved.  This may include, for instance, assigning responsibility for administration of the 
vaccines following delivery to a specific ward, checking the neonates’ vaccination statuses 
before discharge, and ensuring missed doses of vaccine are received if the infants’ return 
for follow-up care.   The following interventions to improving vaccination coverage should 
be considered 106: 
(i) Parental reminders of the dates of scheduled vaccinations – a bulk short message 
service to parents’ cellular phones should be considered; 
(ii) Nurse or clinician reminders of the vaccinations required during the visit using 
charts on the wall, or patient stickers on individual files; 
(iii) Regular monitoring and evaluation of the coverage of vaccinations to ensure 
implementation of the immunization programme; and 
(iv) Improve access to vaccination services provided at McCord Hospital to include the 
casualty and general paediatric outpatient departments.  In addition, all visits by 
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caregivers to McCord Hospital should be considered opportunities to vaccinate the 
infant if present at the time of the visit.   
The attrition rates of infants at McCord Hospital can be improved by sending caregivers’ 
reminders of the date of the scheduled visits – again, bulk short message services could 
facilitate this process.  Mothers of infants who are known to be at high risk for loss to 
follow-up should be intensively counselled on the value of remaining in care for their own 
health and that of the infant.  All infants who are lost to follow-up should be active traced 
and educated to remain in care. 
6.4 RECOMMENDATION FOR FURTHER STUDY 
Although the study observed high rates of attrition and infectious disease morbidity of 
infants born to mothers in the Prevention of Mother-to-Child Transmission programme at 
McCord Hospital, the reasons for poor retention and morbidity were incompletely 
assessed.  In addition, the infant morbidity, mortality and HIV transmission risk may have 
been underestimated due to the high proportion of loss to follow-up in the study.  A key 
area to consider further is the impact of infant feeding practices and maternal nutrition on 
infant morbidity and mortality.  The reasons for high incidence of infant infections at two to 
four months should be studied further.  Maternal socio-economic characteristics and 
paternal factors associated with poor retention should also be explored.  A prospective 
cohort study design is recommended to answer these questions 
6.5 SUMMARY 
McCord Hospital is a good model for integrated maternal and child health services for 
HIV-infected women and their infants.  However, the attrition of these infants represented 
a missed opportunity to improve the health outcomes and the effectiveness of the 
Prevention of Mother-to-Child Transmission programme at McCord Hospital.  Improved 
counselling of women on the health benefits of attending follow-up care for themselves 
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